



Europäisches Patentamt

(19) European Patent Office

Office européen des brevets

(11) Publication number:

0 088 350  
A1

(12)

## EUROPEAN PATENT APPLICATION

(21) Application number: 83102014.4

(51) Int. Cl.: C 07 C 103/52, A 61 K, 37/02

(22) Date of filing: 02.03.83

(30) Priority: 08.03.82 US 355639  
08.03.82 US 355638  
22.03.82 US 360532  
19.01.83 ZA 830362

(43) Date of publication of application: 14.09.83  
Bulletin 83/37

(84) Designated Contracting States: AT BE CH DE FR IT LI  
LU NL SE


(71) Applicant: SCHERING CORPORATION, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 (US)

(72) Inventor: Smith, Elizabeth M., 166 Grove Avenue, Verona New Jersey 07044 (US)  
Inventor: Witkowski, Joseph T., 5 Martha Drive, Morristown New Jersey 07960 (US)  
Inventor: Dall, Ronald J., 128 Union Avenue, Maplewood New Jersey 07040 (US)  
Inventor: Gold, Elijah H., 10 Roosevelt Avenue, West Orange New Jersey 07052 (US)  
Inventor: Neustadt, Bernard R., 24 Brook Place, West Orange New Jersey 07052 (US)  
Inventor: Yehaskel, Albert S., 50 Nottingham Road, Fairlawn New Jersey 07410 (US)


(74) Representative: Antony, Fritz, Dr. et al, P.O. Box 601 Winkelriedstrasse 35, CH-6002 Lucerne (CH)

(54) Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them.

(55) The compounds of the present invention are compounds of the formula



and the pharmaceutically acceptable esters and salts thereof wherein  $\text{R}^1$  and  $\text{R}^5$  independently are hydrogen or lower alkyl; the group



is one of the structures II to VIII specified

A1

In the description, one of  $\text{R}^3$ ,  $\text{R}^4$  and  $\text{R}^5$  is a group  $\text{Z}-(\text{CH}_2)_n-$ , wherein  $\text{Z}$  is selected from  $\text{Z}'$  to  $\text{Z}^{10}$  being as defined in the description and the other of the groups  $\text{R}^3$ ,  $\text{R}^4$  and  $\text{R}^5$  are as also defined. The compounds are useful as antihypertensive agents, in the treatment of congestive heart failure and glaucoma. Their preparation and pharmaceutical compositions are disclosed.

EP

0 088 350 A1


Best Available Copy

Carboxyalkyl dipeptides, processes for their production  
and pharmaceutical compositions containing them.

The present invention relates to carboxyalkyl dipeptides  
5 substituted with groups containing one sulfamoyl group.  
The compounds are useful as antihypertensive agents, in  
the treatment of congestive heart failure and glaucoma.

Carboxyalkyl dipeptides which are useful as inhibitors  
of angiotensinconverting enzyme and as antihypertensive  
agents are known from the published European patent  
10 applications Nos. 12401 and 50800.



The compounds of the present invention are compounds of  
the formula




I

and the pharmaceutically acceptable esters thereof and the pharmaceutically acceptable salts of the free compounds and the esters, wherein R<sup>1</sup> and R<sup>2</sup> independently are hydrogen or lower alkyl;


5 the group -N - C- is one of the structures II to VIII




II




III




IV



V




VI



VII

(wherein B is a saturated or aromatic ring) or




VIII

5 one of R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> is a group Z-(CH<sub>2</sub>)<sub>0-6</sub>-, wherein Z has one of the following values z<sup>1</sup> to z<sup>10</sup>


0088350

$z^1:$




IX

$z^2:$




X

$z^3:$



XI


$z^4:$



XII


5

$z^5:$




XIII

$z^6:$




XIV

$z^7:$




XV

$z^8:$




XVI

$z^9:$



XVII

$z^{10}:$



XVIII

wherein R<sup>8</sup> is Cl or CF<sub>3</sub>;

R<sup>6</sup> is hydrogen or halogen;

R<sup>7</sup> is hydrogen, halogen, carboxy, hydroxy or amino;

5 R<sup>9</sup> and R<sup>10</sup> are independently hydrogen, lower alkyl or halo-lower alkyl and R<sup>9</sup> can also be phenyl or phenyl lower alkyl;

R<sup>11</sup> is hydrogen or lower alkyl;

R<sup>12</sup> is hydrogen, lower alkyl or phenyl lower alkyl;

whereby when R<sup>3</sup> is the group Z-(CH<sub>2</sub>)<sub>0-6</sub>-, then

10 R<sup>3</sup> is Z<sup>1</sup>-(CH<sub>2</sub>)<sub>1-6</sub>-, Z<sup>2</sup>-(CH<sub>2</sub>)<sub>1-6</sub>-, Z<sup>3</sup>-(CH<sub>2</sub>)<sub>1-6</sub>-,  
Z<sup>4</sup>-CH<sub>2</sub>-, Z<sup>5</sup>-(CH<sub>2</sub>)<sub>1-6</sub>-, Z<sup>6</sup>-(CH<sub>2</sub>)<sub>1-6</sub>-, Z<sup>7</sup>-(CH<sub>2</sub>)<sub>1-6</sub>-,  
Z<sup>8</sup>-(CH<sub>2</sub>)<sub>1-6</sub>-, Z<sup>9</sup>-(CH<sub>2</sub>)<sub>1-6</sub>-, or Z<sup>10</sup>-(CH<sub>2</sub>)<sub>1-6</sub>-,

R<sup>4</sup> is lower alkyl, benzyl, benzyloxy, benzylthio, phenoxy,  
or phenylthio,

15 R<sup>5</sup> is hydrogen; and the group -N-C- is one of the structures II to  
VIII;

and when R<sup>4</sup> is the group Z-(CH<sub>2</sub>)<sub>0-6</sub>-, then

R<sup>4</sup> is Z<sup>1</sup>-(CH<sub>2</sub>)<sub>0-6</sub>-, Z<sup>2</sup>-(CH<sub>2</sub>)<sub>0-6</sub>-, Z<sup>3</sup>-(CH<sub>2</sub>)<sub>0-6</sub>-,

Z<sup>4</sup>-(CH<sub>2</sub>)<sub>0-6</sub>-, Z<sup>5</sup>-(CH<sub>2</sub>)<sub>0-6</sub>-, Z<sup>6</sup>-(CH<sub>2</sub>)<sub>0-6</sub>-, Z<sup>7</sup>-(CH<sub>2</sub>)<sub>0-6</sub>-,

20 Z<sup>8</sup>-(CH<sub>2</sub>)<sub>0-6</sub>-, Z<sup>9</sup>-(CH<sub>2</sub>)<sub>0-6</sub>- or Z<sup>10</sup>-(CH<sub>2</sub>)<sub>0-6</sub>- and

R<sup>3</sup> is hydrogen, lower alkyl or amino lower alkyl and

R<sup>5</sup> is hydrogen; and the group -N-C- is one of the structures II to  
VIII;

0088350


- 6a -

and when  $R^5$  is the group  $z-(CH_2)_{0-6}-$ , then  $R^5$  is  $z^1$ ,  $z^2$ ,  
 $z^3$ ,  $z^4$ ,  $z^5$ ,  $z^6$ ,  $z^7$ ,  $z^8$ ,  $z^9$  or  $z^{10}$ ,

$R^3$  is hydrogen, lower alkyl or amino lower alkyl and

$R^4$  is lower alkyl, benzyl, benzyloxy, benzylthio, phenoxy or phenyl-

---



thio; and

the group  $\text{-N} - \text{C}-$  is one of the structures II to VII.



One embodiment of the present invention comprises compounds of formula I, its esters and salts, wherein  $R^4$  is 5 the group  $\text{Z-}(\text{CH}_2)_{0-6}-$ . Among these compounds certain groups of compounds are preferred:

.1) compounds, wherein the group



$\text{-N} - \text{C}-$  is the group of formula II, IV (wherein B is a saturated ring) or VIII, preferably  $R^5$  being hydrogen;

10 .1) compounds, wherein  $R^4$  is  $\text{Z-}(\text{CH}_2)_{0-6}-$ , Z being  $\text{z}^1$ ,  $\text{z}^2$ ,  $\text{z}^3$ ,  $\text{z}^5$ ,  $\text{z}^7$ ,  $\text{z}^8$ ,  $\text{z}^9$  or  $\text{z}^{10}$ ;

.1) compounds, wherein  $R^4$  is  $\text{z}^1-(\text{CH}_2)_2$  or  $3^-$ ,  $\text{z}^2-(\text{CH}_2)_2$  or  $3^-$ ,  $\text{z}^3-(\text{CH}_2)_2$  or  $3^-$ ,  $\text{z}^5-(\text{CH}_2)_2$  or  $3^-$ ,  $\text{z}^7-(\text{CH}_2)_2$  or  $3^-$ ,  $\text{z}^8-(\text{CH}_2)_2$  or  $3^-$ ,  $\text{z}^9-(\text{CH}_2)_2$  or  $3^-$  or 15  $\text{z}^{10}-(\text{CH}_2)_2$  or  $3^-$ ;

.1) compounds, wherein  $R^4$  is  $\text{z}^4$ ;

.1) compounds, wherein  $R^1$  and  $R^2$  are hydrogen;

.1) compounds, wherein  $R^6$  is hydrogen and  $R^7$  is hydrogen or hydroxy;


20 .1) compounds, wherein  $R^9$  and  $R^{10}$  are independently hydrogen or methyl;

.1) compounds, wherein  $R^8$  is chloro;

.1) compounds, wherein  $R^3$  is methyl;


.1) compounds, wherein  $R^1$  and  $R^2$  are independently

25 hydrogen or lower alkyl (preferably hydrogen), the group




$-N - C -$  is the group of formula II or IV, wherein B is a saturated ring and  $R^5$  is hydrogen,  $R^4$  is  $Z^1 - (CH_2)_3 -$ ,  $Z^2 - (CH_2)_3 -$  or  $Z^4$ ,  $R^6$  and  $R^7$  are hydrogen and  $R^8$  is chloro; and  $R^3$  is hydrogen, lower alkyl or amino lower alkyl (preferably methyl);

5 .) of particular interest are compounds, wherein  $R^1$  and  $R^2$  are hydrogen, the group



$-N - C -$  is the group of formula IV wherein B is a saturated ring, and  $R^5$  is hydrogen,  $R^4$  is  $Z^1 - (CH_2)_3 -$  or  $Z^2 - (CH_2)_3 -$ , wherein  $R^6$  is hydrogen,  $R^7$  is hydrogen or hydroxy, and  $R^8$  is chloro, and  $R^3$  is methyl, preferably in the form of its mono-or-di-ethyl ester. Also the analogous compounds, wherein the group



Another embodiment of the present invention comprises

15 compounds of formula I, its esters and salts, wherein  $R^3$  is the group  $Z - (CH_2)_{0-6} -$ . Among these compounds the following groups of compounds are preferred:

.) compounds, wherein the group



$-N - C -$  is the group of formula II, IV (wherein B is a saturated ring) or VIII;

.) compounds, wherein  $R^3$  is  $Z^1-(CH_2)_4-$ ,  $Z^2-(CH_2)_4-$ ,  
 $Z^3-(CH_2)_4-$ ,  $Z^4-CH_2-$ ,  $Z^5-(CH_2)_4-$ ,  $Z^6-(CH_2)_4-$ ,  $Z^7-(CH_2)_4-$ ,  
 $Z^8-(CH_2)_4-$ ,  $Z^9-(CH_2)_4-$  or  $Z^{10}-(CH_2)_4-$ ;

.) compounds, wherein  $R^1$  and  $R^2$  are hydrogen;


5 .) compounds, wherein  $R^6$  is hydrogen and  $R^7$  is hydrogen  
or hydroxy;

.) compounds, wherein  $R^9$  and  $R^{10}$  are independently  
hydrogen or methyl;

.) compounds, wherein  $R^8$  is chloro;


10 .) compounds, wherein  $R^4$  is benzyl or ethyl;

. ) compounds, wherein  $R^1$  and  $R^2$  are independently hydrogen  
or lower alkyl (preferably hydrogen), the group




$-N - C -$  is the group of formula II or IV, wherein B is a  
saturated ring, and  $R^5$  is hydrogen,  $R^3$  is  $Z^1-(CH_2)_4-$ ,  
15  $Z^2-(CH_2)_4-$  or  $Z^4-CH_2-$ ,  $R^6$  and  $R^7$  are hydrogen and  $R^8$  is  
chloro and  $R^4$  is —CH<sub>2</sub>—(S)<sub>m</sub>— wherein m is zero or  
1,

.) of particular interest are compounds, wherein  $R^1$  and  
 $R^2$  are hydrogen, the group




20  $-N - C -$  is the group of formula IV, wherein B is a satu-  
rated ring and  $R^5$  is hydrogen,  $R^3$  is  $Z^1-(CH_2)_4-$  or  
 $Z^2-(CH_2)_4-$ , wherein  $R^6$  and  $R^7$  are hydrogen,  $R^8$  is chloro;  
and  $R^4$  is benzyl, preferably in the form of its mono-or-  
di-ethyl ester. Also the analogous compounds, wherein




Another embodiment of the present invention comprises compounds of formula I, its esters and salts, wherein  $\text{R}^5$  is the group  $\text{Z} - (\text{CH}_2)_{0-6}^-$ . Among these compounds the

5 following groups of compounds are preferred:

. ) compounds, wherein the group



. ) compounds, wherein the group



. ) compounds, wherein  $\text{R}^5$  is  $\text{Z}^1, \text{Z}^2, \text{Z}^3, \text{Z}^5, \text{Z}^7, \text{Z}^8, \text{Z}^9$  or  $\text{Z}^{10}$ ;

. ) compounds, wherein  $\text{R}^1$  and  $\text{R}^2$  are hydrogen;

. ) compounds, wherein R<sup>6</sup> is hydrogen and R<sup>7</sup> is hydrogen or hydroxy;


. ) compounds, wherein R<sup>9</sup> and R<sup>10</sup> are independently hydrogen or methyl;

5 . ) compounds, wherein R<sup>8</sup> is chloro;

. ) compounds, wherein R<sup>3</sup> is methyl;

. ) compounds, wherein R<sup>4</sup> is benzyl or ethyl;

. ) compounds, wherein R<sup>1</sup> and R<sup>2</sup> are independently hydrogen or lower alkyl, the group




The lower alkyl groups, except where noted otherwise,  
15 include straight and branched chain hydrocarbon radicals from one to six carbon atoms, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, hexyl, cyclopropyl, cyclohexyl and the like.

The compounds of this invention form esters. In these esters the hydroxy group of the carboxy groups shown in formula I can be replaced by the same or by different groups which are selected from alkoxy having from 1 to 8

carbon atoms, phenoxy, phenylalkyloxy having from 7 to 10 carbon atoms,  $-\text{OCH}_2\text{OCO}$ -alkyl having from 3 to 8 carbon atoms,  $-\text{OCH}_2\text{CO-phenyl}$ ,  $-\text{O}(\text{CH}_2)_k-\text{O-}$  phenyl wherein k is 1 or 2 and the phenyl ring may be substituted by halogen, hydroxy, trifluoromethyl, alkoxy having from 1 to 6 carbon atoms, alkyl having from 1 to 6 carbon atoms (the phenyl group preferably containing one substituent) and  $-\text{O}(\text{CH}_2)_k-\text{O-naphthyl}$  wherein k is 1 or 2.

Preferred are alkyl esters (the alkyl group being defined as above) and aryl esters, especially the ethyl and benzyl esters. Of particular interest are the monoesters, wherein the carboxy group attached to the group



The compounds of this invention form salts with various inorganic and organic acids and bases which are also within the scope of the invention. Such salts include 5 ammonium salts, alkali metal salts like sodium and potassium salts (which are preferred), alkaline earth metal salts like the calcium and magnesium salts, salts with organic bases e.g., dicyclohexylamine salts, N-methyl-D-glucamine, salts with amino acids like arginine, lysine

10 and the like. Also, salts with organic and inorganic acids may be prepared, e.g., HCl, HBr,  $\text{H}_2\text{SO}_4$ ,  $\text{H}_3\text{PO}_4$ , methanesulfonic acid, toluensulfonic acid, maleic acid, fumaric acid and camphorsulfonic acid. The non-toxic physiologically acceptable salts are preferred, although other salts are also useful, e.g., in isolating or purifying  
15 the product.

This invention includes all possible stereoisomers of the compounds. Preferred stereoisomers are those in which the absolute configurations at each of the three carbon atoms bonded to both a nitrogen and a carbonyl group corresponds most closely to the absolute configuration of L-aminoacids. The preferred compounds contain a cis, syn-octahydro-1*H*-indole-2(S)-carboxylic acid moiety or a 1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid moiety.

Non limiting examples of preferred compounds of the present invention are:

1-*N*-[1(S)-ethoxycarbonyl-5-(4-chloro-3-sulfamoyl)-benzenesulfonaminopentyl)-(S)-alanyl]-*cis*,syn-octahydro-1*H*-indole-2(S)-carboxylic acid,

5 1-*N*-[1(S)-ethoxycarbonyl-5-(4-chloro-3-sulfamoyl)-benzamidopentyl)-(S)-alanyl]-*cis*,syn-octahydro-1*H*-indole-2(S)-carboxylic acid,

1- $\{N-[1(S)-ethoxycarbonyl-5-(4-chloro-2-hydroxy-5-sulfamoyl)-benzamidopentyl)-(S)-alanyl\}$ -cis, syn-octahydro-1*H*-indole-2(S)-carboxylic acid,

10 1- $\{Na-[1(S)-ethoxycarbonyl-3-phenylpropyl]-Ne-[ (4-chloro-3-sulfamoyl)benzenesulfonyl]-(S)-lysyl\}$ -cis, syn-octahydro-1*H*-indole-2(S)-carboxylic acid,

15 1- $\{Na-[1(S)-ethoxycarbonyl-3-phenylpropyl]-Ne-[ (4-chloro-3-sulfamoyl)benzoyl]-(S)-lysyl\}$ -cis, syn-octahydro-1*H*-indole-2(S)-carboxylic acid,

7- (4-chloro-3-sulfamoylbenzamido)-2- $\{N-[1(S)-ethoxycarbonyl-3-phenylpropyl]-(S)-alanyl\}$ -1,2,3,4-tetrahydroisoquinoline-3(S)-carboxylic acid,

1- $\{N-[1(S)-CARBOXY-5-[(4-CHLORO-2-HYDROXY-5-SULFAMOYL)PHENYL] CARBONYL]AMINO]PENTYL-(S)-ALANYL\}$ -CIS, SYN-OCTAHYDRO-1*H*-INDOLE-2(S)-CARBOXYLIC ACID,  
1- $\{N-[1(S)-CARBOXY-5-[(4-CHLORO-3-(N-METHYL SULFAMOYL)PHENYL) CARBONYL]AMINO]PENTYL-(S)-ALANYL\}$ -CIS, SYN-OCTAHYDRO-1*H*-INDOLE-2(S)-CARBOXYLIC ACID,  
1- $\{N-[1(S)-CARBOXY-5-[(4-CHLORO-3-SULFAMOYL PHENYL) CARBONYL]AMINO]PENTYL-(S)-ALANYL\}$ -CIS, SYN-OCTAHYDRO-1*H*-INDOLE-2(S)-CARBOXYLIC ACID,


1-[N-[1(S)-ETHOXCARBONYL-5[(4-CHLORO-2-AMINO-5-SULFAMYLPHENYL)-CARBONYL]AMINO]PENTYL]-(S)ALANYL]-CIS,SYN-OCTAHYDRO-1H-INDOLE-2(S)CARBOXYLIC ACID

1-{N-[1(S)-ethoxycarbonyl-5-[7-chloro-4-oxo-6-sulfamyl-2-phenyl-1,2,3,4-tetrahydro quinazolin-3-yl]pentyl]-(S)-alanyl}-cis,syn-octahydro-1H-indole-2(S) carboxylic acid

or the corresponding <sup>free</sup> ~~fill~~ acids or esters, respectively.

The compounds of the present invention can be produced by one or more of the methods and subroutes depicted in the following equations. Reactive groups not involved in the reactions described below such as amino and carboxy groups may be protected by methods standard in peptide chemistry prior to the coupling reactions and subsequently deprotected to obtain the desired products. Racemates, if obtained by these processes, can be resolved by standard techniques such as column chromatography or fractional crystallization.

A. For the preparation of compounds of formula I, wherein R<sup>1</sup> is hydrogen a ketocompound (XIX) is condensed with a dipeptide (XX) under reduction.




5 In these compounds A, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are as defined above and Pr stands for a free or a protected (e.g. by esterification) hydroxy group.

The ketocompound (XIX) can be condensed with the dipeptide (XX) in aqueous solution, optimally near neutrality, or  
 10 in a suitable organic solvent (for example CH<sub>3</sub>OH) in the presence of a reducing agent such as for example sodium cyanoborohydride to give directly the desired compound I (wherein R<sup>1</sup> is hydrogen). Alternatively, the intermediate Schiff base, enamine, or aminol may be catalytically reduced  
 15 to yield product I, for example, by hydrogen in the presence of palladium on carbon (e.g. 10% palladium on carbon) or of Raney nickel. The ratio of diastereomeric products formed may be altered by the choice of catalyst.


B. Alkylation of a dipeptide (XX) by means of a compound  
 20 of formula (XXI)

0088350



wherein X is chloro, bromo, iodo, alkanesulfonyloxy or :arenesulfonyloxy, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> are as defined above for compounds of formula I and Pr stands for a free or protected (e.g. by esterification) hydroxy group. The reaction can be carried out under basic conditions in water or in an organic solvent.

C. Condensation of an aminoacid (XXII) with an aminoacid (XXIII)



A, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> are as defined above for compounds formula I and Pr stands for a free or protected (e.g. esterification) hydroxy group.


This reaction is well known from peptide chemistry. The reaction can be carried out in the presence of a condensing agent such as for example dicyclohexylcarbodiimide (DCC), diphenylphosphoryl azide (DPPA) and N,N-disuccinimidyl carbonate in CH<sub>3</sub>CN. While, as mentioned above, reactive groups (e.g. hydroxy groups) are protected before the coupling reaction is carried out, the amino group of compound (XXIII)

- 17 -

can be activated, e.g. by means of tetraethyldiphosphit and/or the carboxy group of compound (XXII) can be activated via the intermediacy of active esters such as that derived from 1-hydroxybenzotriazole, its mixed anhydride (derived from a chlorocarbonic acid ester), its azide or dicyclohexylcarbodiimide.

This process is of particular use for the preparation of  
5 compounds wherein the R<sup>3</sup>, R<sup>4</sup> or R<sup>5</sup> contains or is Z<sup>1</sup>, especially wherein R<sup>4</sup> is or contains Z<sup>1</sup>.


D. Condensation of an amino compound (XXIV) with a keto-compound (XXV)



10 under the conditions described for process A.

A; R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> are as defined above for compounds formula I and Pr stands for a free or protected (e.g. by esterification) hydroxy group.

E. Alkylation of an amino compound (XXIV) by means of a compound (XXVI)




XXIV

XXVI

wherein X is chloro, bromo, iodo, alkanesulfonyloxy or arenesulfonyloxy, A, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> are as defined above for compounds of formula I, and Pr stands for a free or protected (e.g. by esterification) hydroxy group. The reaction can be carried out under the conditions described for process B.

F. For the preparation of compounds of formula I, wherein one of R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> is a group Z-(CH<sub>2</sub>)<sub>0-6</sub>-, wherein Z is z<sup>5</sup>, z<sup>6</sup>, z<sup>7</sup>, z<sup>8</sup>, z<sup>9</sup> or z<sup>10</sup> preferably z<sup>7</sup>, z<sup>8</sup> or z<sup>9</sup>:

10 Condensation of a peptide of the general formula (XXX) with a compound containing the desired group (XXXI)




XXX

XXXI


wherein R<sup>1</sup>, R<sup>2</sup> and A are as defined for formula I, Pr is a protected hydroxy group, W<sup>3</sup>, W<sup>4</sup> and W<sup>5</sup> are defined like R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> respectively with the difference that one of W<sup>3</sup>, W<sup>4</sup> and 15 W<sup>5</sup> contains an NH<sub>2</sub>-group instead of the respective z<sup>5</sup> to z<sup>10</sup>-group; and W<sup>6</sup> is z<sup>5</sup>, z<sup>6</sup>, z<sup>7</sup>, z<sup>8</sup>, z<sup>9</sup> or z<sup>10</sup>. The reaction can be carried out in an inert organic solvent, e.g. an alcohol, (preferably ethanol) at reflux temperature.

This reaction may be exemplified by the following Reaction Scheme:



G. For the preparation of compounds of formula I, wherein one of  $R^3$ ,  $R^4$  and  $R^5$  is a group  $Z-(CH_2)_{0-6}-$ , wherein  $Z$  is 5  $z^1$ ,  $z^2$  or  $z^3$ :

condensation of a peptide of formula XXXII with an appropriately substituted compound of formula XXXIII




XXXII


XXXIII

I


wherein R<sup>1</sup>, R<sup>2</sup> and A are as defined for formula I, Pr is a protected hydroxy group, W<sup>7</sup>, W<sup>8</sup> and W<sup>9</sup> are defined like R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> respectively, with the difference that one of W<sup>7</sup>, W<sup>8</sup> and W<sup>9</sup> contains an NH<sub>2</sub>-group instead of the respective z<sup>1</sup>, z<sup>2</sup> or z<sup>3</sup> group, and W<sup>10</sup> is



XXXIV




XXXV



XXXVI


This condensation can be exemplified by the following

Reaction Scheme:




The reaction can be carried out in a suitable solvent (e.g. THF, pyridine or mixture of THF and triethylamine), usually between 0°C and room temperature.

H. For the preparation of compounds of formula I, wherein  
5 one of R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> is a group Z-(CH<sub>2</sub>)<sub>0-6</sub>-, wherein Z is  
Z<sup>4</sup>: condensation of a peptide of formula (XXXVII) with a  
3-halomethylbenzothiadiazine (XXXVIII)



XXXVIII




XXXVII


10 wherein R<sup>1</sup>, R<sup>2</sup> and A are as defined for formula I, Pr is a protected hydroxy group, W<sup>11</sup>, W<sup>12</sup> and W<sup>13</sup> are defined like R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> respectively with the difference that one of W<sup>11</sup>, W<sup>12</sup> and W<sup>13</sup> contains a -SH-group instead of the respective Z<sup>4</sup>-group, and Hal is halogen, preferably chloro.

The reaction is carried out in a suitable solvent (e.g. DMF), preferably in the presence of triethylamine.

I. For the preparation of compounds of formula I, wherein one of R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> is a group Z-(CH<sub>2</sub>)<sub>0-6</sub>-, wherein Z is  
5 Z<sup>5</sup> or Z<sup>6</sup>: condensation of a peptide of formula XXXIX  
with a compound of formula XXXX




wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>9</sup>, R<sup>10</sup> and A are as defined for formula I,  
Pr is a protected hydroxy group, W<sup>14</sup>, W<sup>15</sup> and W<sup>16</sup> are de-  
fined like R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> respectively with the difference  
that one of W<sup>14</sup>, W<sup>15</sup> and W<sup>16</sup> contains the group



instead of the group Z<sup>5</sup> or Z<sup>6</sup> respectively. The reaction can be carried out in an inert organic solvent, e.g. an alcohol, preferably ethanol, under acidic conditions (e.g. by addition of a hydrochloric acid) at reflux temperature.


The starting compounds in these reactions can be prepared according to known methods.

The compound of formula XXII, wherein R<sup>1</sup> is hydrogen can for example be prepared by reacting a keto compound (XIX) 5 with an aminoacid (XXVII)





according to the condition described in process A.

Alternatively, the compound of formula XXII can be prepared by condensing XXIV with a keto acid (XXVIII)



or by condensing





under the conditions described for process B (X being as defined in process B).

The compound XXII can also be prepared analogously to  
5 process G described above.

The starting compound (XXXVII) of process H can for example be prepared from a correspondign compound wherein the respective group  $\text{W}^{11}$ ,  $\text{W}^{12}$  or  $\text{W}^{13}$  is  $-\text{SCHC}_6\text{H}_5$  by reduction with sodium in liquid ammonia.

10 The above processes are followed by setting free protected groups by known methods. Protected carboxy groups, e.g. when, for example, ~~—~~protected by removable ester groups (e.g. Pr being alkoxy,  $\beta$ methoxy, ethoxy, tert. butyloxy), nitrobenzyloxy or bezyloxy, are set free by hydrolysis or  
15 hydrogenation. (Reductive cleavage of a compound, wherein one of the protecting groups (Pr) is benzyloxy and the other protecting group is alkoxy will yield a compound, wherein the benzyloxy group has been replaced by hydroxy

but the alkoxy group has not been replaced.) Hydrolysis can be carried out under acidic conditions (using e.g. a halogen hydracid or trifluoroacetic acid), under basic conditions or by means of photochemical hydrolysis.

- 5 The amino group(s) can be protected by protecting groups such as for example formyl, t-butoxycarbonyl, carbobenzyl-oxy, triphenylmethyl and nitrophenylsulfenyl. These groups can be removed under acidic conditions, e.g. by means of a halogenhydroacid and/or trifluoroacetic acid.
- 10 Esters obtained by the above processes can also be trans-esterified. For example, ethyl esters can be converted to the corresponding benzyl ester with benzyl alcohol under acidic conditions.

As mentioned before the compounds of this invention exist

- 15 in diastereoisomeric forms or in mixtures thereof. The above described syntheses can utilize racemates, enantiomers—or diastereomers as starting materials. Enantiomeric intermediates may be obtained by resolution methods known in the art. When diastereomeric products result
- 20 from the synthetic procedures, the diastereomeric products can be separated by conventional chromatographic or fractional crystallization methods (e.g. described in the European published application No. 12401).

The compounds of this invention form salts with various inorganic and organic acids and bases which are also within the scope of the invention. Such salts include ammonium salts, alkali metal salts like sodium and potassium salts (which are preferred), alkaline earth metal salts like the calcium and magnesium salts, salts with organic bases e.g., dicyclohexylamine salts, N-methyl-D-glucamine, salts with amino acids like arginine, lysine and the like. Also, salts with organic and inorganic acids may be prepared, e.g., HCl, HBr,  $H_2SO_4$ ,  $H_3PO_4$ , methanesulfonic acid, toluensulfonic acid, maleic acid, fumaric acid and camphorsulfonic acid. The non-toxic physiologically acceptable salts are preferred, although other salts are also useful, e.g., in isolating or purifying the product.

The salts may be formed by conventional means, as by reacting the free acid or free base forms of the product with one or more equivalents of the appropriate base or acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is then removed in vacuo or by freeze-drying or by exchanging the cations of an existing salt for another cation on a suitable ion exchange resin.

The compounds of this invention are useful as antihypertensive agents in mammals, including humans, in which the

blood pressure has become abnormally elevated.

The compounds of the present invention can be combined with pharmaceutical carriers and administered in a variety of well known pharmaceutical forms suitable for oral or parenteral administration to provide compositions useful in the treatment of cardiovascular disorders and particularly mammalian hypertension.

The effective dose ( $ED_{50}$ ) of the compounds of this invention will typically be in the range of about 0.01 to about 30mg/kg, preferable of about 0.1 to about 10mg/kg, of mammalian weight, administered in single or divided doses. The exact dose to be administered is dependent upon where the particular compound lies within the above quoted range, as well as upon the age, weight and condition of the individual.

Generally, in treating humans, the compounds of this invention may be administered to patients in need of such treatment in a dosage range of 5 to 500mg per patient generally given several times, thus giving a total daily dose of from 5 to 2000mg per day.

The composition containing the compounds of this invention will preferably contain from about 5 to 250mg of the active compound per dosage unit. These compositions are most preferably administered orally. Typical formulations for 5 oral administration are those such as tablets, capsules, syrups, elixirs or suspensions. Typical injectable formulations include solutions and suspensions.

The typical acceptable pharmaceutical carriers for use in the formulations described above are exemplified by:

10 sugars such as lactose, sucrose, mannitol and sorbitol; starches such as corn starch, tapioca starch and potato starch; cellulose and derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and methyl cellulose; calcium phosphates such as dicalcium phosphate and tri-  
15 calcium phosphate; sodium sulfate; calcium sulfate, polyvinylpyrrolidone, polyvinyl alcohol; stearic acid; alkaline earth metal stearates such as magnesium stearate and calcium stearate, stearic acid, vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil and corn oil;  
20 non-ionic, cationic and anionic surfactants; ethylene glycol polymers; beta-cyclodextrin; fatty alcohols and hydrolyzed cereal solids; as well as other non-toxic compatible fillers, binders, disintegrants, buffers, preservatives, antioxidants, lubricants, flavoring agents, and the like

commonly used in pharmaceutical formlations.

The following examples illustrate the preparation of the compounds of the present invention. The diasteromers prepared as setforth below may be isolated by column chromatography or by fractional crystallization.

In the examples below, octahydroindole-2(S)-carboxylic acid refers to cis,syn-octahydroindole-2(S)-carboxylic acid, also named 3a(S), 7a(S)-octahydroindole-2(S)-carboxylic acid.

Example 1

1-[Na-[1(S)-Ethoxycarbonyl-3-phenylpropyl]-Nε-[ (4-chloro-3-sulfamoyl)benzenesulfonyl]-(S)-lysyl]-cis,syn-octahydro-1H-indole-2(S)-carboxylic acid

5 A. Stir a suspension of 24.0g of Nε-benzyloxycarbonyl-(S)-lysine and 36.0g of ethyl 2-oxo-4-phenylbutanoate acid in 2500ml of absolute ethanol at room temperature for 24 hours. Add 16.0g of sodium cyanoborohydride and stir the resulting mixture at room temperature for 48 hours. Add 80ml of water  
10 and stir the resulting mixture at room temperature for 72 hours. Concentrate this mixture in vacuo at 30°C to give a white residue. Suspend the residue in 1200ml of ice water, add concentrated hydrochloric acid to maintain pH 2-4, and stir this mixture for 2 hours. Absorb this aqueous solution  
15 on 2000ml of XAD-2 (Rohm & Haas Co.) resin. Elute the resin with 16,000ml of water and then with 8000ml of absolute ethanol. Concentrate the ethanol solution and chromatograph the residue on a column of silica gel (3000ml, 60-200 mesh) eluting with chloroform : isopropanol : 7% ammonium hydroxide 1:1:1 (organic layer) to give a white residue. Chromatograph this residue on a column of silica gel (3000ml), eluting with chloroform : isopropanol : 7% ammonium hydroxide 1:1:1 (organic layer) to give fractions A, B, C, and D. Absorb fraction B on a column of silica gel  
20 (1500ml), eluting with chloroform : isopropanol : 7% ammonium hydroxide 1:1:1 (organic layer) to give N -benzyloxycarbonyl-Na-[1(S)-carboethoxy-3-(phenyl)propyl]-(S)-lysine, a white solid,  $[\alpha]_D^{26} +6.1^\circ$  (ethanol), m.p. 114-115°C.  
25 B. Cool a solution of 1.9g of the product of part A and 1.3g of cis,syn-octahydro-1H-indole-2(S)-carboxylic acid benzyl ester in 24ml of dimethylformamide to 0°C under nitrogen. Add dropwise a solution of 0.9 of diphenyl-

phosphorylazide in 6ml of dimethylformamide, followed by a solution of 0.7ml of N-methylmorpholine in 6ml of dimethylformamide, also added dropwise, and stir at room temperature for 18 hours. Pour the reaction solution into water, 5 adjust to pH 8 with 1N NaOH, and extract with ether. Dry the ether layer over magnesium sulfate, and concentrate under vacuum to a yellow oil. Chromatograph the oil on silica gel (1000ml, 60-200 mesh), eluting with hexane : ethyl acetate (1:2) to give 1-[Na-[1(S)-carboethoxy-3-(phenyl)propyl]-N<sup>c</sup>-benzyloxy-carbonyl-(S)-lysyl]-cis,syn-octahydro-1H-indole-2(S)-carboxylic acid, benzyl ester, a 10 yellow oil.

C. Dissolve 1.60g of the product of part B in 150ml of absolute ethanol. Add 0.75g of 10% palladium-on-charcoal 15 and hydrogenate the mixture at 50 psi at room temperature. Filter the reaction mixture and concentrate the filtrate in vacuo to give 1-[Na-[1(S)-ethoxycarbonyl-3-(phenyl)propyl-(S)-lysyl]-cis,syn-octahydro-1H-indole-2(S)-carboxylic acid hydrate, a white foam,  $[\alpha]_D^{26} -42.5$  (ethanol).

20 D. To 4.9g of 1-[Na-[1(S)-[ethoxycarbonyl-3-phenylpropyl)-(S)-lysyl]-cis,syn-octahydro-1H-indole-2(S)-carboxylic acid in 200ml of tetrahydrofuran and 2g of triethylamine at 0-5°C, add 2.9g of 4-chloro-3-sulfamoylbenzenesulfonyl chloride and stir the resulting mixture at room temperature. Concentrate the resulting mixture in vacuo and chromatograph the residue on an Lobar RP-8, size B column (E. Merck) 25 using acetonitrile : water as eluant to give the title compound.

Example 2

1-[Na-[1(S)-Ethoxycarbonyl-3-phenylpropyl]-Nε-[ (4-chloro-3-sulfamoyl)benzoyl]-(S)-lysyl]-cis,syn-octahydro-1H-indole-2 (S)-carboxylic acid

5 Treat 4.9g of 1-[Na[1(S)-ethoxycarbonyl-3-phenylpropyl]-(S)-lysyl]-cis,syn-octahydro-1H-indole-2 (S)-carboxylic acid (obtainable as described in Example 1A to 1C) in 200ml of tetrahydrofuran and 2.0g of triethylamine at 0-5°C with 2.2g of 4-chloro-3-sulfamoyl-benzoyl chloride and stir  
10 the resulting mixture at room temperature. Concentrate the resulting mixture in vacuo and chromatograph the residue on a Labor RP-8, size B column (E. Merck) using acetonitrile : water as eluant to give the title compound.

Example 3

15 1-[Na-[1(S)-Ethoxycarbonyl-3-phenylpropyl]-Nε-[ (4-chloro-3-sulfamoyl)benzenesulfonyl]-(S)-lysyl]-(S)-proline

Substitute 2.17g of 1-[Na-[1(S)-ethoxycarbonyl-3-phenylpropyl]-(S)-lysyl]-(S)-proline for the respectively substituted octahydro-1H-indole-2 (S)-carboxylic acid in Example 1D to obtain the title compound.  
20

Example 4

1-[Na-[1(S)-Ethoxycarbonyl-3-phenylpropyl]-Nε-[ (4-chloro-3-sulfamoyl) benzoyl]-(S)-lysyl]-(S)-proline

Substitute 2.17g of 1-[Na-[1(S)-ethoxycarbonyl-3-phenylpropyl]-(S)-lysyl]-(S)-proline for the respectively substituted octahydro-1H-indole-2 (S)-carboxylic acid in Ex-

ample 2 to obtain the title compound.

Example 5

1-[Na-[1(S)-Carboxy-3-phenylpropyl]-Nε-[ (4-chloro-3-sulf-  
amoyl)benzenesulfonyl]-(S)-lysyl]-cis,syn-octahydro-1H-

5 indole-2(S)-carboxylic acid

A. To a solution of 1.10g of 1-[Na[1(S)-ethoxycarbonyl-  
3-phenylpropyl]-(S)-lysyl]-cis,syn-octahydro-1H-indole-2(S)-  
carboxylic acid (prepared as in Example 1) in 100ml of  
methanol at 0-5°C, add 2.0ml of 2.5N sodium hydroxide so-  
10 lution and stir at room temperature for 24 hours. Add  
20ml of water, concentrate to one-half volume, and stir  
24 hours. Concentrate this solution in vacuo and absorb  
on AG 50W-X2 (100-200 mesh, hydrogen form, Bio-Rad resin)  
(50ml). Place said 50ml of resin on an additional 300ml  
15 of resin, elute the resin with 1200ml of water, and then  
elute with 4% pyridine in water to yield 1-[Na-[1(S)-  
carboxy-3-phenylpropyl]-(S)-lysyl]-cis,syn-octahydro-1H-  
indole-2(S)-carboxylic acid, a white solid, m.p. 165-166°  
[α]<sub>D</sub><sup>26</sup>-8-2 (ethanol).

20 B. Treat 2.45g of the product of Step A with 1.45g of 4-  
chloro-3-sulfamoylbenzenesulfonyl chloride as described in  
Example 1D to give the title compound.

Example 6

1-[Na-[1(S)-Carboxy-3-phenylpropyl]-Nε-[ (4-chloro-3-sulf-  
amoyl)benzoyl-(S)-lysyl]-cis,syn-octahydro-1H-indole-2(S)-  
carboxylic acid

Treat 2.45g of the product from Example 5A with 1.1g of 4-chloro-3-sulfamoylbenzoyl chloride as described in Example 2 to give the title compound.

Example 7

5 1-[N-[1(S)-Carboxy-3-phenylpropyl]-S-[3-(6-chloro-3,4-dihydro-7-sulfamoyl-1,2,4-benzothiadiazinyl-1,1-dioxide)methyl]-(R)-cysteinyl]-cis,syn-octahydro-1H-indole-2(S)-carboxylic acid

A. Stir 10.5g of S-benzyl-L-cysteine and 11.0g of 2-oxo-10 4-phenylbutyric acid, ethyl ester in 1000ml of absolute ethanol at room temperature for 24 hours. Add. 5.28g of sodium cyanoborohydride and stir the resulting mixture at room temperature for 48 hours. Concentrate this mixture in vacuo at 30°C to give a white residue. Suspend the 15 residue in ice-water, add concentrated hydrochloric acid to maintain pH 2-4, and stir this mixture for 1 1/2-2 hours. Absorb this aqueous solution on XAD-2 (Rohm & Haas Co.) resin. Elute the resin with water and then with absolute ethanol. Concentrate the ethanol solution and chromatograph the residue on a column of silica gel using chloroform : isopropanol : 7% ammonium hydroxide 1:1:1 (organic layer) to give N-[1(S)-carboethoxy-3-phenylpropyl]-S-benzyl-(R)-cysteine.

B. Treat 4.0g of the product of part A and 2.6g of cis,syn-octahydro-1H-indole-2(S)-carboxylic acid, benzyl ester in 25 10ml of dimethylformamide at 0° under nitrogen with a solution of 2.75g of diphenylphosphorylazide in 1.0g of N-methylmorpholine in 10ml of dimethylformamide, and stir at room temperature for 18 hours. Pour the reaction solution 30 into water, adjust to pH 8 with 1N, NaOH, and extract with

ether. Wash the combined ether layers with aqueous sodium chloride solution, dry the ether layer over magnesium sulfate, filter, and concentrate in vacuo to give a residue. Chromatograph this residue on silica gel (60-200 mesh)

5 using hexane : ethylacetate to give 1-[N-[1(S)-ethoxy-carbonyl-3-phenylpropyl]-S-benzyl-(R)-cysteinyl]-cis,syn-octahydro-1H-indole-2-(S)-carboxylic acid, benzyl ester.

C. Stir the product of part B in 50ml of a 15-20% solution of hydrobromic in acetic acid under nitrogen for 2 hours, 10 then concentrate to dryness under vacuum at room temperature. Triturate the resultant residue with ether to obtain 1-[N-[1(S)-(ethoxycarbonyl-3-phenylpropyl)-S-benzyl-(R)-cys-teinyl]-cis,syn-octahydro-1H-indole-2(S)-carboxylic acid, hydrobromide.

15 D. React 1.5g of the product from part C in methanol with 3.0ml of 2.5N sodium hydroxide at room temperature for 24 hours and concentrate the resulting mixture in vacuo at room temperature. Absorb the residue on AG 50W-X2 (100-200 mesh, hydrogen form, Bio-Rad) resin. Elute the resin 20 with water and then elute with 4% pyridine in water to yield 1-[N-[1(S)-carboxy-3-phenylpropyl]-S-benzyl-(R)-cysteinyl]-cis,syn-octahydro-1H-indole-2(S)-carboxylic acid, hydro-bromide.

E. Treat 1.0g of product from part D with 0.05g of sodium 25 in 100ml of liquid ammonia. Evaporate and concentrate the resulting mixture to give 1-[N-[1(S)-carboxy-3-phenylpropyl)-(R)-cysteinyl]-cis,syn-octahydro-1H-indole-2(S)-carboxylic acid as the sodium salt.

F. React 0.4g of the product from Step E in 20ml of di-30 methylformamide with 0.36g of 2-bromomethyl-6-chloro-3,4-dihydro-7-sulfamoyl-1,2,4-benzothiadiazine-1,1-dioxide

and triethylamine. Concentrate the resulting mixture and chromatograph on an AG 50W-X2 column eluting with 4% pyridine in water to give the title compound.

Example 8

5 1-[N-[1(R)-Carboxy-2-[S-((3-(6-chloro-3,4-dihydro-7-sulf-  
amoyl-1,2,4-benzothiadiazinyl-1,1-dioxide)methyl)thio]-  
ethyl]]-(S)-alanyl]-cis,syn-octahydro-1H-indole-2(S)-car-  
boxylic acid

A. Stir 100g of S-benzyl-L-cysteine ethyl ester hydrochloride, 132g of benzyl pyruvate, and 10g of 3A molecular sieves in 8 liters of ethanol for 18 hours under nitrogen. Add dropwise a solution of 52g of sodium cyanoborohydride in 100ml of ethanol, stir at room temperature for 24 hours, filter, then concentrate the filtrate at room temperature under vacuum. Suspend the resultant residue in 100ml of water and 500ml of ether and adjust the mixture to pH 8 with 1N HCl. Wash the organic layer with saturated sodium chloride solution, dry over sodium sulfate, and filter. Adjust the filtrate to pH 2 with 3M ethereal HCl, decant the supernatant, wash the resulting oily precipitate with 200ml of ether, and mix with saturated aqueous sodium bicarbonate to obtain a solution of pH 8. Extract the mixture with 1 liter of ether, dry the ether layer over sodium sulfate and concentrate at room temperature to give N-[1(R)-carboethoxy-2-(benzylthio)ethyl]-(R,S)-alanine, benzyl ester, an amber oil. Thin layer chromatography in ethyl acetate : hexane (15:85) may be used to separate the two isomers (isomer A at Rf = 0.36, and isomer B at Rf = 0.28), or the procedure may be continued on the mixture.

30 B. Add 50g of the product of part A to 1800ml of a 15-20%

solution of hydrobromic-acetic acid and heat at 50°C for 20 hours. Concentrate the resultant mixture to dryness under vacuum, and wash the resultant oily residue with ether until free of acetic acid to produce N-[1(R)-carboxyethyl-2(benzyl-  
5 thio)ethyl]-(R,S)-alanine hydrobromide, an amber oil.

C. Cool a solution of 50.5g of the product of part B and 33.4g of cis,syn-octahydroindole-2(S)-carboxylic acid benzyl ester in 1 liter of dimethylformamide to 0°C under nitrogen, add dropwise a solution of 35.5g of diphenylphosphorylazide  
10 in 1 liter of dimethylformamide, followed by a solution of 33.4g of N-methylmorpholine in 200ml of dimethylformamide, also added dropwise, and stir at room temperature for 18 hours. Pour the reaction solution into 3 liters of water, adjust to pH 8 with 1N NaOH, and extract with 4 x 1 liter  
15 of ether. Wash the combined ether layers with 1 liter of aqueous sodium chloride, dry the ether layer over magnesium sulfate, filter, and concentrate under vacuum to an amber oil.

Chromatograph the resultant oil on 2kg of silica gel (60-  
20 200 mesh) using ether : hexane (90:10). Collect components having Rf 0.38 and Rf 0.61 as indicated by thin layer chromatography on silica gel eluted with ether. The isomer with Rf 0.61 is 1-[N-[1(R)-carboethoxy-2-(benzylthio)ethyl]-(S)-  
25 alanyl]-cis,syn-octahydro-1H-indole-2(S)-carboxylic acid,  
benzyl ester.

D. Stir 0.70g of the (S)-alanyl product of part C and 25ml of a 15-20% solution of hydrobromic-acetic acid under nitrogen for 2 hours, then concentrate to dryness under vacuum at room temperature. Triturate the resultant residue with ether  
30 and filter to obtain 1-[N-[1(R)-carboethoxy-2-(benzylthio)-ethyl]-(S)-alanyl]-cis,syn-octahydro-1H-indole-2(S)-carboxylic acid, hydrobromide as a tan solid, m.p. 124-125°C.

E. To a solution of 10.6g of the product of Step D in 500ml of methanol, add 24ml for 2.5N sodium hydroxide solution and stir at room temperature for 24 hours. Concentrate this solution in vacuo and absorb on AG 50W-2 (Bio-Rad) resin (100-200 mesh, hydrogen form). Elute the resin with water and then elute with 4% pyridine in water to yield 1-{N-[1(R)-carboxy-2-(benzylthio)ethyl]-(S)-alanyl}-cis,syn-octahydro-1H-indole-2(S)-carboxylic acid.

5      F. Treat 4.22g of the product of Step E with 0.23g of sodium in 200ml of liquid ammonia. Evaporate the ammonia and absorb the residue on AG 50W-2 (Bio-Rad) resin (100-200 mesh, hydrogen form). Elute the resin with water and then elute with 4% pyridine in water to yield 1-{N-[1(R)-carboxy-2-(mercapto)ethyl]-(S)-alanyl}-cis,syn-octahydro-1H-indole-2(S)-carboxylic acid.

10     G. React 2.2g of the product of Step F in 20ml of dimethylformamide with 2.4g of 3-bromomethyl-6-chloro-3,4-dihydro-7-sulfamoyl-1,2,4-benzothiadiazine-1,1-dioxide and triethylamine. Concentrate the resulting mixture to give the title compound.

15

Example 9

1-{N-[1(S)-Ethoxycarbonyl-5-(4-chloro-3-sulfamoyl)-benzenesulfonaminopentyl]-(S)-alanyl}-cis,syn-octahydro-1H-indole-2(S)-carboxylic acid

25 A. Dissolve 27.0g of ethyl indole-2-carboxylate in 250ml of trifluoroacetic acid. Add 2.05g of platinum oxide, hydrogenate the mixture at 50 lb/in<sup>2</sup> at room temperature. Filter the mixture and concentrate the filtrate in vacuo to give a residue. Suspend the residue in ether and treat

with cold dilute sodium hydroxide solution. Dry the organic layer over magnesium sulfate and concentrate it to give ethyl octahydroindole-2-carboxylate, a pale yellow oil.

B. Dissolve 116g of 10-d-camphorsulfonic acid in 1 liter  
5 of warm ethyl acetate and add a solution of 86g of the product of part A in 1 liter of ethyl acetate. Allow the mixture to crystallize, heat to reflux, cool to room temperature, and filter. Recrystallize the filter cake from a mixture of 500ml of isopropanol and 1800ml ethyl acetate,  
10 filter and dry the crystals to obtain 2-(S)-carboethoxy-  
cis,syn-octahydro-1H-indole, d-10-camphorsulfonate,  
m.p. 192-193°C.

C. Slurry 10g of the product of part B in 1 liter of ether, adjust to pH 11 with aqueous sodium hydroxide, and  
15 stir for 5 minutes. Wash the organic layer with sodium chloride solution, dry over magnesium sulfate, filter, and evaporate in vacuo at room temperature to obtain 2(S)-carboethoxy-cis,syn-octahydro-1H-indole as a colorless oil. Dissolve the resultant oil in 50ml of methynol containing  
20 23ml of 1N sodium hydroxide, stir at 25°C for 30 minutes, adjust to pH 7 with 1N hydrochloric acid, and evaporate the solvent to give cis,syn-octahydro-1H-indole-2(S)-carboxylic acid.

D. Cool 23ml of benzyl alcohol to 0°C under nitrogen and  
25 add 5.95g of thionyl chloride dropwise over 15 minutes, maintaining the temperature at 0°C. Add the product of part C, stir for 1 hour at 0°C, then stir for 24 hours at room temperature. Pour the resulting mixture into 500ml of ether, stir 1 hour under nitrogen, then allow to stand under  
30 nitrogen until the solution is clear. Decant the supernatant, wash the precipitate with 25ml ether, then slurry the precipitate in 200ml ether and adjust to pH 8-9 with

1N sodium hydroxide. Stir 5 minutes, wash the organic layer with sodium chloride solution, dry over magnesium sulfate, filter and evaporate in vacuo at room temperature to obtain cis,syn-octahydroindole-2(S)-carboxylic acid,

5      benzyl ester as a colorless oil (TLC in ether: one spot, Rf 0.3).

E. To 26g of the product of Step D in 100ml of dichloromethane and 7.8ml of pyridine add 11.0g of pyruvoyl chloride and stir the resulting mixture at room temperature.

10     Extract the reaction mixture with water and dry the organic layer over magnesium sulfate. Concentrate the dichloromethane solution in vacuo and distill the residue to give 1-pyruvoyl-cis,syn-octahydro-1H-indole-2(S)-carboxylic acid, benzyl ester.

15     F. To 20g of the product from Step E in 400ml of ethanol, add 2.0g of 10% palladium-on-charcoal and hydrogenate at 50 psi at room temperature. Filter the resulting mixture and concentrate the filtrate in vacuo to give 1-pyruvoyl-cis,syn-octahydro-1H-indole-2(S) carboxylic acid.

20     G. React 6.20g of N-(benzyloxycarbonyl)-L-lysine ethyl ester in 20ml of tetrahydrofuran with 4.8g of 1-pyruvoyl-cis,syn-octahydro-1H-indole-2(S)-carboxylic acid and add 20ml of molecular sieves 4A (Rohm and Haas). Stir the resulting mixture for 4 hours, add 12g of sodium cyanoborohydride in 20ml of methanol and

25     stir the reaction mixture 20 hours. Filter, concentrate to dryness, and partition the residue between water and dichloromethane. Absorb the aqueous phase on strong acidic ion-exchange resin and elute with 4% pyridine in water to give 1-[N-[1(S)-ethoxycarbonyl-5-benzyloxycarbonylaminopentyl]-(R,S)-

30     alanyl]-cis,syn-octahydro-1H-indole-2(S)-carboxylic acid. Separate the isomers on a column of silica gel using  $\text{CHCl}_3$  : isopropanol : 7% ammonium hydroxide 1:1:1 (organic) as eluent to give 1- N-[1(S)-

ethoxycarbonyl-5-benzyloxycarbonylaminopentyl]-  
cis,syn-octahydro-1H-indole-2(S)-carboxylic acid.

H. Hydrogenate the product from Step G in 300ml of ethanol using 1g of 10% palladium-on-charcoal at 50 psi at room 5 temperature. Filter the mixture and concentrate the filtrate to give 1-[N-[1(S)-ethoxycarbonyl-5-aminopentyl]-  
(S)-alanyl]-cis,syn-octahydro-1H-indole-2(S)-carboxylic acid.

I. React 1.01g of the product of Step H in 20ml of tetrahydrofuran and 0.25g of triethylamine with 0.75g of 4-10 chloro-3-sulfamoylbenzenesulfonyl chloride and stir the resulting mixture at room temperature. Concentrate the resulting mixture in vacuo and chromatograph the residue on a Lobar RP-8 (E. Merck) size B column using acetonitrile : water as eluant to give the title compound.

15

Example 10

1-[N-[1(S)-Ethoxycarbonyl-5-(4-chloro-3-sulfamoyl-benzamido-pentyl)-(S)-alanyl]-cis,syn-octahydro-1H-indole-2(S)-carboxylic acid

Treat 1.01g of 1-[N-[1(S)-ethoxycarbonyl-5-aminopentyl]-  
20 (S)-alanyl]-cis,syn-octahydro-1H-indole-2(S)-carboxylic acid, obtained according to Example 9H, in 20ml of tetrahydrofuran and 0.25g of triethylamine with 0.55g of 4-chloro-3-sulfamoylbenzoyl chloride and stir the resulting mixture at room temperature. Concentrate the resulting mixture in vacuo and chromatograph the residue on a Lobar 25 RP-8 (E. Merck) size B column using acetonitrile : water as eluant to give the title compound.

Example 11

1-[N-[1(S)-Carboxy-5-(4-chloro-3-sulfamoyl)benzamidopentyl]-(S)-alanyl]-cis,syn-octahydro-1H-indole-2(S)-carboxylic acid

A. To 4.04g of 1-[N-[1(S)-ethoxycarbonyl-5-aminopentyl]-(S)-alanyl]-cis,syn-octahydro-1H-indole-2(S)-carboxylic acid in 100ml of methanol : water 1:1 add 8ml of 2.5N NaOH at 0-5°C and then stir the resulting mixture at room temperature for 24 hours. Concentrate the resulting mixture and absorb on AG 50W-2 (Bio-Rad) resin (100-200 mesh, hydrogen form). Elute the resin with water, and then elute with 4% pyridine in water to yield 1-[N-[1(S)-carboxy-5-aminopentyl]-(S)-alanyl]-cis,syn-octahydro-1H-indole-2(S)-carboxylic acid.

B. React 0.95g of the product from Step 11A with 0.55g of 4-chloro-3-sulfamoylbenzoyl chloride as described in Example 10 to give the title compound.

Example 12

1-[N-[1(S)-Carboxy-5-(4-chloro-3-sulfamoyl)benzenesulfonamidopentyl]-(S)-alanyl]-cis,syn-octahydro-1H-indole-2(S)-carboxylic acid

Treat 0.95g of the product from Example 11A with 0.75g of 4-chloro-3-sulfamoylbenzenesulfonyl chloride as described in Example 9I to give the title compound.

Example 13

1-[N-[1(S)-Ethoxycarbonyl-5-(4-chloro-3-sulfamoyl)-benzenesulfonamidopentyl]-(R,S)-alanyl]-(S)-proline

A. Make a solution of N<sub>ε</sub>-benzyloxycarbonyl-L-lysine ethyl ester hydrochloride (2.94g) in water (10ml) basic with 15ml of saturated aqueous potassium bicarbonate and extract with CH<sub>2</sub>Cl<sub>2</sub>. Dry the extract over MgSO<sub>4</sub> and concentrate to dryness. Dissolve the residue, N<sub>ε</sub>-benzyloxycarbonyl-L-lysine ethyl ester, in tetrahydrofuran (20ml) and pyruvoyl-proline (555mg) and add powdered No. 4A molecular sieves (1.0g). Stir the mixture at room temperature for 4 hours.

10 Add sodium cyanoborohydride (630mg) in 1ml of methanol over 2 hours and stir the mixture overnight. Filter the mixture, concentrate to dryness, and partition the residue between water (10ml) and CH<sub>2</sub>Cl<sub>2</sub> (15ml). Absorb the aqueous phase on strong acid ion-exchange resin and elute with 4% pyridine in water to yield 470mg of 1-[N-[1(S)-ethoxycarbonyl-5-

15 benzyloxycarbonylaminopentyl]-(R,S)-alanyl]-S-proline. Remove the protecting group by hydrogenation in ethanol : water 1:1 over 10% Pd/C catalyst at 40 psi. Filter the mixture and take the filtrate to dryness. Chromatograph the residue in methanol on an LH-20 column to give the

20 desired 1-[N-[1(S)-ethoxycarbonyl-5-aminopentyl]-(R,S)-alanyl]-(S)-proline.

B. Condense 0.90g of the product from Step A with 0.75g of 4-chloro-3-sulfamoylbenzenesulfonyl chloride as described in Example 9I to give the title compound.

25

Example 14

1-[N-[1(S)-Ethoxycarbonyl-5-(4-chloro-3-sulfamoyl)-benzamidopentyl]-(R,S)-alanyl]-(S)-proline

React 0.90g of the product of Example 13A with 0.55g of 4-chloro-3-sulfamoylbenzoylchloride as described in Example 10 to give the title compound.

Example 15

1-[N-[1(S)-Carboxy-5-(4-chloro-3-sulfamoyl)benzene-sulfonamidopentyl]-R,S)-alanyl}-(S)-proline

A. Treat 3.50g of the product of Example 13A in 100ml of  
5 methanol : water 1:1 with 8.0ml of 2.5*N* NaOH as described  
in Example 11A to give 1-[N-[1(S)-carboxy-5-aminopentyl]-  
(R,S)-alanyl}-(S)-proline.

B. Condense 0.80g of the product of Step A with 0.75g of  
4-chloro-3-sulfamoylbenzenesulfonyl chloride as described  
10 in Example 9I to give the title compound.

Example 16

1-[N-[ (S)-Carboxy-5-(4-chloro-3-sulfamoyl)benzamidopentyl]-  
(R,S)-alanyl}-(S)-proline

React 0.80g of the product of Example 15A with 0.55g of  
15 4-chloro-3-sulfamoylbenzoyl chloride as described in Ex-  
ample 10 to give the title compound.

Example 17

7-(4-Chloro-3-sulfamoylbenzamido)-2-[N-[1(S)-carboxy-3-phenylpropyl]-  
(S)-alanyl}-1,2,3,4-tetrahydroisoquinoline-3(S)-carboxylic acid

A. Dissolve 1,2,3,4-tetrahydro-7-nitroisoquinoline-3(S)-carboxylic acid ethyl ester (0.1 mole) in ethanol and add the solution to 10% palladium on carbon (1.0g) in a hydrogenation bottle. Hydrogenate the mixture at 30 psi, at

room temperature until the reduction is complete as indicated by thin layer chromatography. Remove the catalyst by filtration and evaporate the solvent under reduced pressure to obtain 7-amino-1,2,3,4-tetrahydroisoquinoline-3-(S)-carboxylic acid ethyl ester.

5 (The preparation of 1,2,3,4-tetrahydro-7-nitroisoquinoline-3(S)-carboxylic acid is described in US patent 4,064,274.)

10 B. Treat 7-amino-1,2,3,4-tetrahydroisoquinoline-3(S)-carboxylic acid ethyl ester (Step A) (0.1 mole) with benzyl alcohol (0.5 mole) and p-toluenesulfonic acid (0.22 mole) in toluene at reflux overnight. Evaporate the solvent under reduced pressure to obtain the p-toluenesulfonic acid  
15 salt of the product. Add this salt to aqueous sodium bicarbonate solution with stirring. Extract the mixture with chloroform, dry the extract with magnesium sulfate and evaporate the solvent under reduced pressure to obtain 7-amino-1,2,3,4-tetrahydroisoquinoline-3(S)-carboxylic acid  
20 benzyl ester.

C. Add a solution of 4-chloro-3-sulfamoylbenzoyl chloride (0.1 mole) in tetrahydrofuran to a solution of product of Step B in tetrahydrofuran containing triethylamine (0.1 mole). When the reaction is complete as indicated by thin  
25 layer chromatography, remove the triethylamine hydrochloride by filtration and evaporate the solvent at reduced pressure. Purify the residue by chromatography to obtain 7-(4-chloro-3-sulfamoylbenzamido)-1,2,3,4-tetrahydroisoquinoline-3(S)-carboxylic acid benzyl ester.

30 D. Cool a solution of N-[1(S)-carboethoxy-3-phenylpropyl]-(S)-alanine (0.01 mole) and the benzyl ester (0.01 mole) from Step C in dry dimethylformamide to 0°C. Add N-methylmorpholine (0.01 mole) with stirring, then add dropwise,

with stirring, a solution of diphenylphosphoryl azide (0.01 mole) in dry dimethylformamide while maintaining the temperature at 0°C. Stir the reaction for one hour at 0°C and overnight at room temperature. Dilute the mixture with

5 ethyl acetate and wash with aqueous sodium bicarbonate. Dry the organic solution with magnesium sulfate and evaporate the solvent under reduced pressure. Purify the residue by chromatography to give 7-(4-chloro-3-sulfamoylbenzamido)-  
2-{N-[1(S)-carboethoxy-3-phenylpropyl]-(S)-alanyl}-1,2,3,4-  
10 tetrahydroisoquinoline-3-(S)-carboxylic acid benzyl ester.

E. Add a solution of 0.01 mole of the benzyl ester from Step D in ethanol to 10% palladium on charcoal (0.5g) in a hydrogenation bottle. Hydrogenate the mixture at 60 psi, at room temperature until removal of benzyl group is complete as indicated by thin layer chromatography. Remove the catalyst by filtration and evaporate the solvent under reduced pressure to obtain 7-(4-chloro-3-sulfamoylbenz-

15 amido)-2-{N-[1(S)-carboethoxy-3-phenylpropyl]-(S)-alanyl}-1,2,3,4-tetrahydroisoquinoline-3(S)-carboxylic acid.

20 F. Stir a solution of 0.01 mole of the product from Step E in water containing sodium hydroxide (0.022 mole) at room temperature until the reaction is complete as indicated by thin layer chromatography. Add methanol to the reaction and then add 0.022 equivalents of Dowex-50(H+) with stirring.  
25 Remove the resin by filtration and evaporate the solvent under reduced pressure. Purify the product by chromatography to obtain the title compound.

Example 18

7-(4-Chloro-3-sulfamoylbenzenesulfonamido)-2-[N-[1(S)-carboxy-3-phenylpropyl]-(S)-alanyl]-1,2,3,4-tetrahydroisoquinoline-3(S)-carboxylic acid

- 5 A. Follow the procedure of Example 17C using 4-chloro-3-sulfamoylbenzenesulfonyl chloride in place of 4-chloro-3-sulfamoylbenzoyl chloride to obtain 7-(4-chloro-3-sulfamoylbenzoyl chloride to obtain 7-(4-chloro-3-sulfamoylbenzene-  
sulfoamido)-1,2,3,4-tetrahydroisoquinoline-3(S)-carboxylic  
10 acid benzyl ester.
- B. Couple the product from Step A with N-[1(S)-carboethoxy-3-phenylpropyl]-(S)-alanine following the procedure of Example 17D. Chromatograph the crude product to obtain  
7-(4-chloro-3-sulfamoylbenzenesulfonamido)-2-[N-[1(S)-  
15 carboethoxy-3-phenylpropyl]-(S)-alanyl]-1,2,3,4-tetrahydroisoquinoline-3(S)-carboxylic acid benzyl ester.
- C. Subject the benzyl ester from Step B to hydrogenolysis as described in Example 17E to obtain 7-(4-chloro-3-sulfamoylbenzenesulfonamido)-2-[N-[1(S)-carboethoxy-3-  
20 phenylpropyl]-(S)-alanyl]-1,2,3,4-tetrahydroisoquinoline-3(S)-carboxylic acid.
- D. Treat the product from Step C with aqueous sodium hydroxide followed by Dowex-50(H<sup>+</sup>) as described in Example 17F to obtain the title compound.

Example 19

5-(4-Chloro-3-sulfamoylbenzamido)-1-[N-[1(S)-carboxy-2-phenylpropyl]-(S)-alanyl]-octahydro-1H-indole-2-carboxylic acid

5 A. Following the procedure of Example 17A, substitute 5-nitroindole-2-carboxylic acid ethyl ester for 1,2,3,4-tetrahydro-7-nitroisoquinoline-3(S)-carboxylic acid ethyl ester to obtain 5-aminoindole-2-carboxylic acid ethyl ester.

10 B. Dissolve 5-aminoindole-2-carboxylic acid ethyl ester in trifluoroacetic acid containing PtO<sub>2</sub>. Hydrogenate at 60 psi on a Parr shaker for 24 hours. Distill the trifluoroacetic acid at reduced pressure and dissolve the residue in ethyl acetate. Filter and adjust to pH 9 with 1N NaOH. Dry the organic layer over MgSO<sub>4</sub> and distill the solvent 15 at reduced pressure to obtain 5-aminooctahydro-1H-indole-2-carboxylic acid ethyl ester.

C. Following the procedure of Example 17B, substitute 5-aminooctahydro-1H-indole-2-carboxylic acid ethyl ester for 7-amino-1,2,3,4-tetrahydroisoquinoline-3(S)-carboxylic acid ethyl ester to obtain 5-aminooctahydro-1H-indole-2-carboxylic acid benzyl ester.

Analogously following the procedures of Examples 17C, 17D, 17E and 17F obtain 5-(4-chloro-3-sulfamoylbenzamido)octahydro-1H-indole-2-carboxylic acid benzyl ester,

25 5-(4-chloro-3-sulfamoylbenzamido)-1-[N-[1(S)-carboethoxy-3-phenylpropyl]-(S)-alanyl]-octahydro-1H-indole-2-carboxylic acid benzyl ester,

5-(4-chloro-3-sulfamoylbenzamido)-1-[N-[1(S)-carboethoxy-3-phenylpropyl]-(S)-alanyl]-octahydro-1H-indole-2-carboxylic 30 acid and the title compound.

Example 20

5-(4-Chloro-3-sulfamoylbenzenesulfonamido)-1-[N-[1(S)-carboxy-3-phenylpropyl]- (S)-alanyl]-octahydro-1H-indole-2-carboxylic acid

5 A. Following the procedures of Example 18A, substitute 5-aminooctahydro-1H-indole-2-carboxylic acid benzyl ester for 7-amino-1,2,3,4-tetrahydroisoquinoline-3(S)-carboxylic acid benzyl ester and 4-chloro-3-sulfamoylbenzenesulfonyl chloride for 4-chloro-2-sulfamoylbenzoyl chloride to obtain  
10 5-(4-chloro-3-sulfamoylbenzenesulfonamido)-octahydro-1H-indole-2-carboxylic acid benzyl ester.

B. Following the procedures of Examples 17D, 17E and 17F obtain 5-(4-chloro-3-sulfamoylbenzenesulfonamido)-1-[N-[1(S)-carboethoxy-3-phenylpropyl]- (S)-alanyl]-octahydro-1H-indole-2-carboxylic acid benzyl ester,  
15 5-(4-chloro-3-sulfamoylbenzenesulfonamido)-1-[N-[1(S)-carboethoxy-3-phenylpropyl]- (S)-alanyl]-octahydro-1H-indole-3-carboxylic acid and the title compound.

Example 21

20 1-[N-[1(S)-Ethoxycarbonyl-5-(4-chloro-3-sulfamoylbenzamido)pentyl]- (S)-alanyl]-cis,syn-octahydro-1H-indole-2(S)-carboxylic acid hydrochloride

A. N-[1(S)-ethoxycarbonyl-5-(benzyloxycarbonylamino)pentyl]- (S)-alanine.  
25 Dissolve 17g of N-[1(S)-ethoxycarbonyl-5-(benzyloxycarbonylamino)pentyl]- (S)-alanine, t-butyl ester in 150ml of trifluoroacetic acid at 5°C. Stir at room temperature for .5hr. and then concentrate at room temperature in vacuo.

Triturate the residue with ether and dry under vacuum to give the title compound.

B. 1-[N-[1(S)-ethoxycarbonyl-5-(benzyloxycarbonylamino)-pentyl]-(S)-alanyl]-cis,syn-octahydro-1H-indole-2(S)-carboxylic acid benzyl ester.

In 5ml of DMF, dissolve 0.7g of N-[1(S)-ethoxycarbonyl-5-(benzyloxycarbonylamino)pentyl]-(S)-alanine, 0.325g of cis,syn-octahydro-1H-indole-2(S)-carboxylic acid benzyl ester, 0.24g of 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride, and 0.20g of 1-hydroxybenzotriazole. Stir this solution under nitrogen for 18 hr. and then concentrate at room temperature in vacuo. Partition between ether and water. Dry the organic layer ( $MgSO_4$ ) and concentrate at room temperature in vacuo to give the title compound.

C. 1-[N-[1(S)-ethoxycarbonyl-5-aminopentyl]-(S)-alanyl]-cis,syn-octahydro-1H-indole-2(S)-carboxylic acid.

In 80ml of ethanol dissolve 3.7g of 1-[N-[1(S)-ethoxycarbonyl-5-(benzyloxycarbonylamino)pentyl]-(S)-alanyl]-cis,syn-octahydro-1H-indole-2(S)-carboxylic acid benzyl ester. To this add 1g of 20% palladium hydroxide on carbon. Hydrogenate this mixture at 60 psi for 18 hr. Filter and concentrate at room temperature in vacuo. Triturate the oily residue with ether and filter to give the title compound, m.p. 160°C (decomp.),  $[\alpha]_D^{26}$  -40.7° (MEOH).

D. 1-[N-[1(S)-ethoxycarbonyl-5-(4-chloro-3-sulfamoyl-benzamido)pentyl]-(S)-alanyl]-cis,syn-octahydro-1H-indole-2(S)-carboxylic acid hydrochloride.

30 Dissolve 0.7g of 1-[N-[1(S)-ethoxycarbonyl-5-aminopentyl]-(S)-alanyl]-cis,syn-octahydro-1H-indole-2(S)-carboxylic acid and 0.4g of triethyl amine in 40ml of tetrahydro-

furan and cool to 5°C. To this solution add dropwise a solution of 0.48g of 4-chloro-3-sulfamoylbenzoyl chloride in 20ml of tetrahydrofuran. Stir for 1 hr. at 5°C and 1 hr. at 25°C. Filter and concentrate in vacuo. Dis-

5 solve the residue in 200ml of dichloromethane and acidify with HCl-gas. Decant and triturate the residue several times with dichloromethane to give the title compound, m.p. 185°C,  $[\alpha]_D^{26} -20^\circ$  (MeOH).

10

Example 22

1-[N-[1(S)-Ethoxycarbonyl-5-(4-chloro-3-sulfamoylbenzamido)pentyl]- (S)-alanyl]-cis,syn-octahydro-1H-indole-2(S)-carboxylic acid

A. N-[1(S)-ethoxycarbonyl-5-(benzyloxycarbonylamino)pentyl]- (S)-alanine, t-butyl ester.

Dissolve 60g of Nε-benzyloxycarbonyl-(S)-lysine, ethyl ester and 90g of t-butyl bromopropionate and 22g of triethylamine in 200ml of DMF. Heat this soution at 70°C for 18 hr. Concentrate in vacuo and dissolve the residue in ethyl acetate.. Wash organic layer with water and brine. Dry organic layer ( $MgSO_4$ ) and concentrate in vacuo. Chromatograph the residue on silica gel (100-200 mesh) using ether : hexane (1:1) as solvent. Elute SR-isomer and then the title compound. Thin layer chromatography in ether : hexane 1:1 shows the SR-isomer at 0.2 and the SS-isomer at 0.1

B. N-[1(S)-ethoxycarbonyl-5-aminopentyl]- (S)-alanine t-butyl ester.

Dissolve 10g of N-[1(S)-ethoxycarbonyl-5-(benzyloxycarbonylamino)pentyl]- (S)-alanine, t-butyl ester in 40ml of ethanol. Add 3.0g of 20% palladium hydroxide on

carbon. Hydrogenate at 60 psi for 18 hr. Filter and concentrate in vacuo to give title compound.

C. N-[1(S)-ethoxycarbonyl-5-(4-chloro-3-sulfamoylbenzamido)pentyl]-(S)-alanine, t-butyl ester.

5 Dissolve 1.0g of N-[1(S)-ethoxycarbonyl-5-aminopentyl]-(S)-alanine, t-butyl ester in 50ml of THF. Add 0.3g of triethylamine. Cool to 5°C under nitrogen. Add, dropwise, with stirring a solution of 0.8g of 4-chloro-3-sulfamoyl benzoyl chloride in 30ml of THF. Warm to room temperature and stir for 10 hr. Filter and concentrate in vacuo. Dissolve residue in ethyl acetate and wash with water and brine. Dry organic layer ( $MgSO_4$ ) and concentrate in vacuo to give the title compound. Purify by chromatography on silica gel using ethyl acetate as eluant.

15 D. N[1(S)-ethoxycarbonyl-5-(4-chloro-3-sulfamoylbenzamido)pentyl]-(S)-alanine, hydrochloride.

Dissolve 0.75g of N-[1(S)-ethoxycarbonyl-5-(4-chloro-3-sulfamoylbenzamido)pentyl]-(S)-alanine, t-butyl ester in 10ml of dioxane saturated with HCl gas. Keep at room temperature 18 hr. Concentrate in vacuo and triturate the residue with ether to give title compound.

E. 1-[N-[1(S)-ethoxycarbonyl-5-(4-chloro-3-sulfamoylbenzamido)pentyl]-(S)-alanyl]-cis,syn-octahydro-1H-indole-2(S)-carboxylic acid, benzyl ester.

25 In 20ml of DMF dissolve 0.75g of N-[1(S)-ethoxycarbonyl-5-(4-chloro-3-sulfamoylbenzamido)pentyl]-(S)-alanine HCl, 0.39g of cis,syn-octahydro-1H-indole-2(S)-carboxylic acid benzyl ester, 0.40g of 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide HCl, 0.23g of 1-hydroxybenzotriazole and 0.15g of N-methyl morpholine. Stir under nitrogen for 18 hr., concentrate at room temperature (0.03 mm) and partition residue between ethyl acetate and water. Dry organic

layer ( $MgSO_4$ ) and concentrate in vacuo to give an oil.

Chromatograph the oil on silica gel using ethyl acetate as eluant to give the title compound.

F. 1-{N-[1(S)-ethoxycarbonyl-5-(4-chloro-3-sulfamoylbenzamido)pentyl]- (S)-alanyl}-cis, syn-octahydro-1*H*-indole-2(S)-carboxylic acid.

Dissolve 0.05g of 1-{N-[1(S)-ethoxycarbonyl-5-(4-chloro-3-sulfamoylbenzamido)pentyl]- (S)-alanyl}-cis, syn-octahydro-1*H*-indole-2(S)-carboxylic acid benzyl ester in 5ml of 20% HBr in glacial acetic acid and allow to stand for 4 hr. Concentrate at room temperature (0.03 mm) and triturate with ether to yield product in the form of its hydrobromide salt. Generate the free base by dissolving the hydrobromide salt in 20% aqueous ethanol and absorbing on a strongly acidic ion exchange column (Bio-Rad AG 50w-X2). Elute with pyridine : water 4:96 and concentrate eluant in vacuo to yield title compound. Generate HCl salt of title compound by adding title compound to dichloromethane and HCl gas to give title compound in the form of its hydrochloride. m.p. 185°C [ $\alpha$ ]<sub>D</sub><sup>26</sup>-20° (MeOH).

Example 23

Treat the benzyl ester from example 17-C with N-carbo-benzoxy-alanine-N-hydroxysuccinimide ester (0.10 mole) in dimethylformamide at room temperature. When the reaction is complete as indicated by thin layer chromatography, evaporate the solvent at reduced pressure. Add ethyl acetate and wash with aqueous sodium bicarbonate solution. Dry the organic solution with magnesium sulfate and evaporate the solvent at reduced pressure. Purify the residue by chromatography. Dissolve this product in ethanol and add the solution to 10% palladium on charcoal (1.0g) in a hydrogenation bottle. Hydrogenate the mixture at 30 psi, until the reaction is complete as indicated by thin layer chromatography. Filter the mixture and evaporate the solvent at reduced pressure to give 7-(4-chloro-3-sulfamoyl-benzamido)-2-[(S)-alanyl]-1,2,3,4-tetrahydroisoquinoline-3(S)-carboxylic acid. Dissolve 7-(4-chloro-3-sulfamoyl-benzamido)-2-[(S)-alanyl]-1,2,3,4-tetrahydroisoquinoline-3(S)-carboxylic acid (0.10 mole) in 100ml of absolute ethanol and add 2-oxo-4-phenylbutyric acid, ethyl ester (0.30 mole). Add 50ml of 3 Angstrom molecular sieve pellets and stir the resulting mixture at room temperature for 18 hrs. Filter the mixture and treat the filtrate with sodium cyanoborohydride (0.30 mole) at room temperature for 2 hrs. Concentrate the mixture under reduced pressure, dilute the oil with dilute hydrochloric acid and stir at room temperature for one hour. Absorb the aqueous solution on XAD-2 resin (Rohm & Haas Co.). Elute the resin with water and then with methanol. Concentrate the methanol solution and purify the residue by chromatography to obtain

7-(4-Chloro-3-Sulfamoylbenzamido)-2- N-[1(S)-Carboethoxy-3-Phenylpropyl]- (S)-Alanyl -1,2,3,4-Tetrahydroisoquinoline-3- (S)-Carboxylic Acid

Example 24

Add ethyl 2-bromo-4-phenylbutanoate (0.10 mole) to a solution of 7-(4-chloro-3-sulfamoylbenzamido)-2-[ (S)-alanyl]-1,2,3,4-tetrahydroisoquinoline-3(S)-carboxylic acid (0.10 mole) and triethylamine (0.20 mole) in 200ml of dimethylformamide and heat the mixture at 70°C for 18 hrs. Remove the solvent at reduced pressure and purify the residue by ion-exchange chromatography to give the product as a mixture of diastereoisomers.

Purify this mixture by chromatography to obtain

7-(4-Chloro-3-Sulfamoylbenzamido)-2- N-[1(S)-Carboethoxy-3-Phenylpropyl]- (S)-Alanyl -1,2,3,4-Tetrahydroisoquinoline-3- (S)-Carboxylic Acid

Example 25

1-{N-[1(S)-ethoxycarbonyl-5-[3-hydroxy-3-(4-chloro-3-sulfamoylphenyl)phthalimidine-2-yl]pentyl}- (S)-alanyl]-cis, syn-octahydro-1E-indole-2(S) carboxylic acid.

Dissolve 3.4g (0.01 mole) of 3-hydroxy-3-(4-chloro-3-sulfamylphthalimidine, 4g (0.01 mole) of 1-{N-[1(S)-ethoxycarbonyl-5-amino-pentyl}- (S)-alanyl]-cis, syn-octahydro-1E-indole-2-(S) carboxylic acid and 2g (0.01g) of p-toluenesulfonic acid monohydrate in 10ml of N,N-dimethylformamide. Stir at 25°C for 2 days then concentrate at room temperature under vacuum. Chromatograph the crude product on an acid ion exchange column (Dowex-50) using water followed by 4% aqueous pyridine followed by chromatography on Sephadex LH-20 (methanol) to obtain the product.


Example 26

1-[N-[1(S)-ethoxycarbonyl-5-[7-chloro-4-oxo-6-sulfamyl-2-phenyl-1,2,3,4-tetrahydro quinazolin-3-yl]pentyl)-(S)-alanyl]-cis,syn-octahydro-1*H*-indole-2(S) carboxylic acid hydrochloride.

Dissolve 3.8g (0.01 mole) of 6-chloro-7-sulfamyl-isotoic anhydride and 4g (0.01 mole) of 1-[N-[1(S)-ethoxycarbonyl-5-aminopentyl)-(S)-alanyl]-cis,syn-octahydro-1*H*-indole-2-(S)-carboxylic acid in 20ml of pyridine. Stir mixture until gas evolution stops (3 hrs). Concentrate at room temperature under vacuum. Chromatograph the crude product on an acid ion exchange column (Dowex-50) using water followed by 4% aqueous pyridine to obtain 1-[N-[1(S)-ethoxycarbonyl-5-[(4-chloro-2-amino-5-sulfamylphenyl)carbonyl]amino]pentyl)-(S)-alanyl]-cis,syn-octahydro-1*H*-indole-2(S) carboxylic acid. HCl salt m.p. 180°C(d)  $[\alpha]_D^{26} = -16.6^\circ$  (methanol C= 0.7)

Dissolve the above intermediate in 20ml of acetic acid and add 2g (0.02 mole) of benzaldehyde. Stir for 3 days and concentrate at room temperature under vacuum. Chromatograph the residue on a strong acid ion exchange column (Dowex-50) using water followed by 4% aqueous pyridine. Concentrate under vacuum and dissolve the residue in ethanol ether. Crystallize with HCl gas and dilute with ether to cause the product to precipitate as a white solid. m.p. 180°C(d)









The following compounds exemplify the compounds of formula I, which can be prepared according to the described processes and the examples. Other esters and the corresponding free acids are equally important.










| No. | Z | $\text{-N} \text{---} \text{CR}_2^5$ |
|-----|---|--------------------------------------|
| 1   |   |                                      |
| 2   |   |                                      |
| 3   |   |                                      |
| 4   |   |                                      |

| No. | Z | $\text{--N}(\text{---CH---})\text{CR}_2^5$ |
|-----|---|--|
| 5   |   |  |
| 6   |   |  |
| 7   |   |  |
| 8   |   |  |

0088350





| No. | Z   |    |
|-----|---|---|
| 9   |    |    |
| 10  |    |    |
| 11  |   |  |
| 12  |  |  |
| 13  |  |  |


| No.     | Z   | $\begin{array}{c} \text{R}^5 \\ \curvearrowleft \text{A} \\   \\ -\text{N}-\text{CR}_2 \end{array}$ |
|---------|---|---|
| 14      |    |                  |
| 15      |   |                 |
| 16      |  |                |
| 5<br>17 |  |                |

| No. | Z | R <sup>5</sup> |
|-----|---|----------------|
| 18  |   |                |
| 19  |   |                |
| 20  |   |                |
| 21  |   |                |
| 22  |   |                |












0088350









- 59 -

| No. | Z  |  |
|-----|--|--|
| 23  |   |   |
| 24  |  |  |



| No. | Z |  |
|-----|---|--|
|     |   | $\begin{array}{c} \text{R}^5 \\   \\ \text{-N}-\text{C}-\text{R}_2 \\   \\ \text{A} \end{array}$ |
| 25  |   |  |
| 26  |   |  |
| 27  |   |  |
| 28  |   |  |







| No. | Z   |    |
|-----|---|---|
| 29  |    |    |
| 30  |   |   |
| 31  |  |  |
| 32  |  |  |
| 33  |  |  |

| No. | Z   | $\begin{array}{c} \text{R} \\   \\ \text{-N}-\text{CR}_2 \\   \\ \text{A} \end{array}$ |
|-----|---|--|
| 34  |    |     |
| 35  |   |    |
| 36  |  |   |
| 37  |  |   |










| No. | Z | $\text{--N}(\text{---})\text{CR}_2^5$ |
|-----|---|---------------------------------------|
| 38  |   |                                       |
| 39  |   |                                       |
| 40  |   |                                       |
| 41  |   |                                       |
| 42  |   |                                       |











| No. | Z | $\text{--N}(\text{---})\text{CR}_2^{\text{S}}$ |
|-----|---|--|
| 43  |   |  |
| 44  |   |  |
| 45  |   |  |
| 46  |   |  |

| $  \begin{array}{c}  \text{H}_5\text{C}_2 \quad \text{OOC} \\    \quad \quad   \\  \text{Z}-\text{(CH}_2\text{)}_4-\text{CH}-\text{NH}-\text{CH}-\text{C(O)-N}-\text{C} \xrightarrow{\text{A}} \text{R}^5 \\    \quad \quad   \\  \text{R}^2 \quad \text{COOH}  \end{array}  $ |   |                                       |
|--|---|---------------------------------------|
| No.  | Z | $\xrightarrow{\text{A}}$ $\text{R}^5$ |
| 47   |   |                                       |
| 48   |   |                                       |
| 49   |   |                                       |
| 50   |   |                                       |
| 51   |   |                                       |








|  |   |   |
|--|---|---|
| No.  | Z   |    |
| 52   |   |    |
| 53   |  |  |
|  |   |   |
|  |   |   |
|  |   |   |






| No. | R <sup>3</sup> | A |
|-----|----------------|---|
| 54  |                |   |
| 55  |                |   |
| 56  |                |   |
| 57  |                |   |









| No. | $R^3$  |    |
|-----|--|---|
| 58  |     |    |
| 59  |    |   |
| 60  |  |  |
| 61  |   |  |

| No. | $R^3$  | $\begin{array}{c} \text{R}^5 \\   \\ -\text{N}-\text{C}(\text{A})-\text{CR}_2- \end{array}$ |
|-----|--|---|
| 62  |    |          |
| 63  |   |         |
| 64  |  |        |
| 65  |   |        |
| 66  |  |        |

| No. | $R^3$  | $\begin{array}{c} R^5 \\ \curvearrowleft A \\   \\ -N-CR_2- \end{array}$ |
|-----|--|--|
| 67  | $\text{H}_2\text{NSO}_2-\text{C}_6\text{H}_3(\text{Cl})-\text{CH}_2-\text{CO}-\text{NH}-\text{CH}_2-\text{CH}_2-\text{CH}_2-$            | $-\text{N}-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-$             |
| 68  | $\text{H}_2\text{NSO}_2-\text{C}_6\text{H}_3(\text{Cl})-\text{CH}_2-\text{SO}_2-\text{NH}-\text{CH}_2-\text{CH}_2-\text{CH}_2-$          | $-\text{N}-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-$             |
| 69  | $\text{H}_2\text{NSO}_2-\text{C}_6\text{H}_3(\text{Cl})-\text{CH}_2-\text{CH}_2-\text{NH}-\text{CH}_2-\text{CH}_2-\text{CH}_2-$          | $-\text{N}-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-$             |
| 70  | $\text{H}_2\text{NSO}_2-\text{C}_6\text{H}_3(\text{Cl})-\text{CH}_2-\text{CH}_2-\text{NH}-\text{CH}_2-\text{S}-\text{CH}_2-\text{CH}_2-$ | $-\text{N}-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-$             |

| No.     | $R^3$  |    |
|---------|--|---|
| 71      |     |    |
| 72      |    |   |
| 73      |  |  |
| 5<br>74 |   |  |

| No. | $R^3$   | $\begin{array}{c} R^5 \\ \backslash \\ A \\ / \\ -N-CR_2- \end{array}$                |
|-----|---|---|
| 75  |    |    |
| 76  |   |   |
| 77  |  |  |
| 78  |  |  |
| 79  |  |  |

| No.     | $R^3$  | $\begin{array}{c} \text{R}^5 \\   \\ \text{A} \\   \\ -\text{N}-\text{CR}_2- \end{array}$ |
|---------|--|---|
| 80      |     |        |
| 81      |   |       |
| 82      |  |      |
| 5<br>83 |   |      |

| No. | $R^3$ | $\begin{array}{c} \text{R}^5 \\   \\ \text{A} \\   \\ -\text{N}-\text{CR}_2- \end{array}$ |
|-----|-------|---|
| 84  |       |   |
| 85  |       |   |
| 86  |       |   |
| 87  |       |   |






| No. | $R^3$   | $-N - CR_2^-$  |
|-----|---|--|
| 88  | <p>Chemical structure 88: 2-chloro-3-(4-sulfamoylbutyl)-4-hydroxy-5-methyl-1,2-dihydro-1H-pyridine-6-carbonyl.</p>  | <p>Diagram: A thiazolidine ring with two sulfur atoms at positions 4 and 5. A substituent labeled 'A' is shown at position 2, and a substituent labeled <math>R^5</math> is shown at position 3.</p> |
| 89  | <p>Chemical structure 89: 2-chloro-3-(4-sulfamoylbutyl)-4-methyl-1,2-dihydro-1H-pyridine-6-carbonyl.</p>            | <p>Diagram: A thiazolidine ring with two sulfur atoms at positions 4 and 5. A substituent labeled 'A' is shown at position 2, and a substituent labeled <math>R^5</math> is shown at position 3.</p> |
| 90  | <p>Chemical structure 90: 4-(4-sulfamoylbutyl)-2-(trifluoromethyl)-1-phenyl-1,2-dihydro-1H-pyridine-6-carbonyl.</p> | <p>Diagram: A thiazolidine ring with two sulfur atoms at positions 4 and 5. A substituent labeled 'A' is shown at position 2, and a substituent labeled <math>R^5</math> is shown at position 3.</p> |
| 91  | <p>Chemical structure 91: 2-chloro-3-(4-sulfamoylbutyl)-4-(methylamino)-1,2-dihydro-1H-pyridine-6-carbonyl.</p>     | <p>Diagram: A thiazolidine ring with two sulfur atoms at positions 4 and 5. A substituent labeled 'A' is shown at position 2, and a substituent labeled <math>R^5</math> is shown at position 3.</p> |
| 92  | <p>Chemical structure 92: 2-chloro-3-(4-sulfamoylbutyl)-4-hydroxy-1,2-dihydro-1H-pyridine-6-carbonyl.</p>           | <p>Diagram: A thiazolidine ring with two sulfur atoms at positions 4 and 5. A substituent labeled 'A' is shown at position 2, and a substituent labeled <math>R^5</math> is shown at position 3.</p> |

0088350

- 76 -

| No. | $R^3$                              | $-N - \begin{array}{c} A \\ \diagup \\ R^5 \\ \diagdown \\ R^2 \end{array} - COOH$ |
|-----|------------------------------------|--|
| 93  | $\text{H}_2\text{NSO}_2$<br>Cl<br> |  |
| 94  | $\text{H}_2\text{NSO}_2$<br>Cl<br> |  |
| 95  | $\text{H}_2\text{NSO}_2$<br>Cl<br> |  |

- 77 -










| No.     | $R^3$  | $\begin{array}{c} A \\ \diagdown \\ -N-CR_2- \\ \diagup \\ R^5 \end{array}$           |
|---------|--|---|
| 96      | $\text{H}_2\text{NSO}_2$<br>Cl<br>   |    |
| 97      | $\text{H}_2\text{NSO}_2$<br>Cl<br>  |  |
| 98      | $\text{H}_2\text{NSO}_2$<br>Cl<br> |  |
| 5<br>99 | $\text{H}_2\text{NSO}_2$<br>Cl<br> |  |












0088350









- 78 -









| No. | $R^3$   | $\begin{array}{c} \text{A} \\ \diagup \\ \text{-N}-\text{CR}_2-\text{R}^5 \\ \diagdown \end{array}$                            |
|-----|---|--|
| 100 | $\begin{array}{c} \text{H}_2\text{NSO}_2 \\   \\ \text{Cl} \text{---} \text{C}_6\text{H}_3 \text{---} \text{SO}_2-\text{NH}-\text{(CH}_2)_4-\end{array}$  | $\begin{array}{c} \text{S} \\ \diagup \\ \text{C}_4\text{H}_8 \text{---} \text{S} \\ \diagdown \\ \text{-N---CH-} \end{array}$ |
| 101 | $\begin{array}{c} \text{H}_2\text{NSO}_2 \\   \\ \text{Cl} \text{---} \text{C}_6\text{H}_3 \text{---} \text{NH} \text{---} \text{C}_2\text{H}_4 \text{---} \text{S} \text{---} \text{CH}_2-\end{array}$ | $\begin{array}{c} \text{S} \\ \diagup \\ \text{C}_4\text{H}_8 \text{---} \text{S} \\ \diagdown \\ \text{-N---CH-} \end{array}$ |












| No.      | Z | -N-A-Z- CR2- |
|----------|---|--------------|
| 102      |   |              |
| 103      |   |              |
| 5<br>104 |   |              |
| 105      |   |              |










| No. | Z   |    |
|-----|---|---|
| 106 |    |    |
| 107 |   |   |
| 108 |  |  |
| 109 |  |  |










| No. | Z   |    |
|-----|---|---|
| 110 |    |    |
| 111 |   |   |
| 112 |  |  |
| 5   |  |  |
|     |  |  |

| No.      | Z   |    |
|----------|---|---|
| 115      |    |    |
| 116      |   |   |
| 117      |  |  |
| 5<br>118 |  |  |


| No. | Z   | $\begin{array}{c} Z \\   \\ A \\ \diagdown \\ -N-CR_2- \end{array}$                   |
|-----|---|---|
| 119 |    |    |
| 120 |    |    |
| 121 |  |  |
| 122 |  |  |
| 5   |   |   |

| No. | Z   |    |
|-----|---|---|
| 123 |    |    |
| 124 |   |   |
| 125 |  |  |
| 126 |  |  |
| 127 |  |  |

| No. | Z   |    |
|-----|---|---|
| 141 |    |    |
| 142 |   |   |
| 143 |  |  |
| 144 |  |  |


| No. | Z   |    |
|-----|---|---|
| 145 |    |    |
| 146 |   |   |
| 147 |  |  |
| 5   |  |  |


| No. | Z | $\text{--N} \text{---} \text{CR}_2\text{---}$ |
|-----|---|---|
| 149 |   |   |
| 150 |   |   |
| 151 |   |   |
| 152 |   |   |
| 153 |   |   |


















| No. | Z | Z |
|-----|---|---|
| 154 |   |   |
| 155 |   |   |
| 5   |   |   |
| 157 |   |   |


0088350



| No. | $R^3$ |  |
|-----|-------|---|
| 158 |       |   |
| 159 |       |   |
| 160 |       |   |
| 161 |       |   |







| No. | $R^3$  |    |
|-----|--|---|
| 162 |    |    |
| 163 |   |   |
| 164 |  |  |
| 165 |  |  |
| 166 |  |  |










| No. | $R^3$  |    |
|-----|--|---|
| 167 |    |    |
| 168 |   |   |
| 169 |  |  |
|     |  |   |










| No. | R <sup>3</sup>   |   |
|-----|--|---|
| 170 | A benzyl group (-CH <sub>2</sub> OCH <sub>2</sub> ) is attached to a central carbon atom. This carbon is also bonded to an amide group (-NH-CH <sub>2</sub> -C(=O)-N(A)-), a carboxylic acid group (-COOH), and two other groups, R <sup>2</sup> and R <sup>5</sup> , which are connected by a curved line labeled 'A'.          | A bicyclic system consisting of a cyclohexane ring fused with a cyclopentane ring. The nitrogen atom is located at the 1-position of the cyclopentane ring, and it is bonded to a methyl group (-CH <sub>3</sub> ). |
| 171 | A benzyl group (-CH <sub>2</sub> OCH <sub>2</sub> ) is attached to a central carbon atom. This carbon is also bonded to an amide group (-NH-CH <sub>2</sub> -SO <sub>2</sub> -NH-), a carboxylic acid group (-COOH), and two other groups, R <sup>2</sup> and R <sup>5</sup> , which are connected by a curved line labeled 'A'. | A bicyclic system consisting of a cyclohexane ring fused with a cyclopentane ring. The nitrogen atom is located at the 1-position of the cyclopentane ring, and it is bonded to a methyl group (-CH <sub>3</sub> ). |
| 172 | A benzyl group (-CH <sub>2</sub> OCH <sub>2</sub> ) is attached to a central carbon atom. This carbon is also bonded to an amide group (-NH-CH <sub>2</sub> -C(=O)-NH-), a carboxylic acid group (-COOH), and two other groups, R <sup>2</sup> and R <sup>5</sup> , which are connected by a curved line labeled 'A'.            | A bicyclic system consisting of a cyclohexane ring fused with a cyclopentane ring. The nitrogen atom is located at the 1-position of the cyclopentane ring, and it is bonded to a methyl group (-CH <sub>3</sub> ). |
| 173 | A benzyl group (-CH <sub>2</sub> OCH <sub>2</sub> ) is attached to a central carbon atom. This carbon is also bonded to an amide group (-NH-CH <sub>2</sub> -C(=O)-NH-), a carboxylic acid group (-COOH), and two other groups, R <sup>2</sup> and R <sup>5</sup> , which are connected by a curved line labeled 'A'.            | A bicyclic system consisting of a cyclohexane ring fused with a cyclopentane ring. The nitrogen atom is located at the 1-position of the cyclopentane ring, and it is bonded to a methyl group (-CH <sub>3</sub> ). |

| No. | $R^3$   |  |
|-----|---|--|
| 174 | <br>$\text{H}_2\text{NSO}_2$<br>Cl<br>$\text{CO}-\text{NH}-(\text{CH}_2)_4-$            | <br>$\text{-N}(\text{R}^5)-\text{CR}_2-$ |
| 175 | <br>$\text{H}_2\text{NSO}_2$<br>Cl<br>$\text{SO}_2-\text{NH}-(\text{CH}_2)_4-$          | <br>$\text{-N}(\text{R}^5)-\text{CH}-$   |
| 176 | <br>$\text{H}_2\text{NSO}_2$<br>$\text{CF}_3$<br>$\text{CO}-\text{NH}-(\text{CH}_2)_4-$ | <br>$\text{-N}(\text{R}^5)-\text{CH}-$   |
| 177 | <br>$\text{H}_2\text{NSO}_2$<br>Cl<br>$\text{CO}-\text{NH}-(\text{CH}_2)_4-$<br>OH      | <br>$\text{-N}(\text{R}^5)-\text{CH}-$   |
| 178 | <br>$\text{H}_2\text{NSO}_2$<br>Cl<br>$\text{CO}-\text{NH}-(\text{CH}_2)_4-$            | <br>$\text{-N}(\text{R}^5)-\text{CH}-$   |





| NO. | R <sup>3</sup>  |   |
|-----|---|---|
| 179 |    |    |
| 180 |   |   |
| 181 |  |  |
|     |   |   |










|  |  |   |
|--|--|---|
| No.  | $R^3$  | $-N - CR_2 -$   |
| 182  |    |    |
| 183  |  |  |
| 184  |  |  |
| 185  |  |  |


| No. | $R^3$   | $\begin{array}{c} \text{A} \\ \curvearrowleft \\ -\text{N}-\text{CR}_2- \end{array}$ |
|-----|---|--|
| 186 | $\begin{array}{c} \text{H}_2\text{NSO}_2 \\   \\ \text{Cl} \text{---} \text{C}_6\text{H}_3 \text{---} \text{CO---NH---(CH}_2\text{)}_4\text{---} \end{array}$                   |  |
| 187 | $\begin{array}{c} \text{H}_2\text{NSO}_2 \\   \\ \text{Cl} \text{---} \text{C}_6\text{H}_3 \text{---} \text{SO}_2\text{---NH---(CH}_2\text{)}_4\text{---} \end{array}$          |  |
| 188 | $\begin{array}{c} \text{H}_2\text{NSO}_2 \\   \\ \text{CF}_3 \text{---} \text{C}_6\text{H}_3 \text{---} \text{C=O---NH---(CH}_2\text{)}_4\text{---} \end{array}$                |  |
| 189 | $\begin{array}{c} \text{H}_2\text{NSO}_2 \\   \\ \text{Cl} \text{---} \text{C}_6\text{H}_3 \text{---} \text{CO---NH---(CH}_2\text{)}_4\text{---} \\   \\ \text{OH} \end{array}$ |  |
| 190 | $\begin{array}{c} \text{H}_2\text{NSO}_2 \\   \\ \text{Cl} \text{---} \text{C}_6\text{H}_3 \text{---} \text{CO---NH---(CH}_2\text{)}_4\text{---} \end{array}$                   |  |

| No. | $R^3$  |    |
|-----|--|---|
| 191 |    |    |
| 192 |   |   |
| 193 |  |  |
|     |  |   |










| No. | $R^3$ | $-N - CR_2 -$ |
|-----|-------|---------------|
| 194 |       |               |
| 195 |       |               |
| 196 |       |               |
| 197 |       |               |

| No. | $R^3$ |    |
|-----|-------|---|
| 198 |       |    |
| 199 |       |   |
| 200 |       |  |
| 201 |       |  |
| 202 |       |  |










| No. | R <sup>3</sup>   |   |
|-----|--|---|
| 203 |    | <br>A:      |
| 204 |   | <br>A:     |
| 205 |  | <br>A:  |
|     |  |   |




| No. | Z |  |
|-----|---|--|
| 206 |   |  |
| 207 |   |  |
| 208 |   |  |
| 209 |   |  |









| No. | Z   |    |
|-----|---|---|
| 210 |    |    |
| 211 |   |   |
| 212 |  |  |
| 213 |  |  |
| 5   |   |   |










| No. | Z |  |
|-----|---|--|
| 214 |   |  |
| 215 |   |  |
| 216 |   |  |
| 217 |   |  |


| No. | Z   |    |
|-----|---|---|
| 218 |    |    |
| 219 |   |   |
| 220 |  |  |
| 5   |  |  |
|     |   |   |

0088350












| No. | Z   |    |
|-----|---|---|
| 222 |    |    |
| 223 |  |  |
| 224 |  |  |
| 225 |  |  |

| No.  | Z   |    |
|------|---|---|
| 226. |    |    |
| 227  |    |   |
| 228  |  |  |
| 5.   |  |  |
|      |   |   |



| No. | Z |  |
|-----|---|--|
| 230 |   |  |
| 231 |   |  |
| 232 |   |  |
| 233 |   |  |

| NO. | Z   |    |
|-----|---|---|
| 234 |    |    |
| 235 |   |   |
| 236 |  |  |
| 5   |  |  |
| 238 |   |   |

The following examples of formulation describe in detail compositions that are illustrative of the present invention. It will be apparent to those skilled in the art that many modifications, both of materials and methods,

5 may be practiced without departing from the purpose and intent of this disclosure.

In the formulation - examples the active ingredients are as follows:

Active ingredient A:

10  $1-\{N\alpha-[1(S)-ethoxycarbonyl-3-phenylpropyl]-Ne-[ (4-chloro-3-sulfamoyl)benzenesulfonyl]-(S)-lysyl\}-cis, syn-octahydro-1H-indole-2(S)-carboxylic acid.$

Active ingredient B:

15  $1-\{N-[1(R)-carboxy-2-[S-((3-(6-chloro-3,4-dihydro-7-sulfamoyl-1,2,4-benzothiadiazinyl-1,1-dioxide)methyl)thio)ethyl]]-(S)-alanyl\}-cis, syn-octahydro-1H-indole-2(S)-carboxylic acid.$

Active ingredient C:

20  $7-(4-chloro-3-sulfamoylbenzamido)-2-\{N-[1(S)-carboethoxy-3-phenylpropyl]-(S)-alanyl\}-1,2,3,4-tetrahydroisoquinoline-3(S)-carboxylic acid.$

Formulation 1

| <u>Capsule</u>      | <u>Amount (mg)</u> |       |
|---------------------|--------------------|-------|
| Active ingredient A | 250.0              | 125.0 |
| Lactose             | 173.0              | 86.5  |
| 5 Corn Starch       | 75.0               | 37.5  |
| Magnesium Stearate  | 2.0                | 1.0   |
|                     | 500.0              | 250.0 |

Blend the active ingredient, lactose and corn starch until uniform; then blend the magnesium stearate into the resulting powder. Encapsulate the mixture into suitably sized two-piece hard gelatin capsules.

Formulation 2

| <u>Tablet</u>                | <u>Amount (mg)</u> |              |
|------------------------------|--------------------|--------------|
| Active ingredient A          | 250.0              | 125.0        |
| 15 Lactose                   | 161.0              | 80.5         |
| Corn Starch                  | 12.0               | 6.0          |
| Water (per thousand tablets) | 120 ml             | 60 ml        |
|                              | (evaporates)       | (evaporates) |
| Corn Starch                  | 75.0               | 37.5         |
| 20 Magnesium Stearate        | 2.0                | 1.0          |
|                              | 500.0              | 250.0        |

Blend the active ingredient with the lactose until uniform. Blend the smaller quantity of corn starch with the water and add the resulting corn starch paste, then mix until a uniform wet mass is formed. Add the remaining corn starch to the remaining wet mass and mix until uniform granules are obtained. Screen the granules through a suitable milling machine, using a 3/4 inch stainless steel screen. Dry the milled granules in a suitable drying oven until the desired moisture content is obtained. Mill the dried granules through a suitable milling machine using a 16 mesh stainless steel screen. Blend in the magnesium stearate and compress the resulting mixture into tablets of desired shape, thickness, hardness and disintegration.

0088350

- 111 -

Formulation 3

| <u>Injectable Solution</u>  | <u>mg/ml</u> |
|-----------------------------|--------------|
| Active ingredient A         | 5.00         |
| Methyl p-hydroxybenzoate    | 0.80         |
| 5 Propyl p-hydroxybenzoate  | 0.10         |
| Disodium Edetate            | 0.10         |
| Citric Acid Monohydrate     | 0.08         |
| Dextrose                    | 40.0         |
| Water for injection qs. ad. | 1.0 ml       |

10 Dissolve the p-hydroxybenzoates in a portion of water for injection at 60-70°C and cool the solution to 25-35°C. Charge and dissolve all other excipients and the active ingredient. Bring the solution to final volume, filter it through a sterilizing membrane and  
15 fill into sterile containers.

008350

- 112 -

Formulation 4

| <u>Capsule</u>      | <u>Amount (mg)</u> |              |
|---------------------|--------------------|--------------|
| Active ingredient B | 250.0              | 125.0        |
| Lactose             | 173.0              | 86.5         |
| 5 Corn Starch       | 75.0               | 37.5         |
| Magnesium Stearate  | 2.0                | 1.0          |
|                     | <u>500.0</u>       | <u>250.0</u> |

Blend the active ingredient, lactose and corn starch until uniform; then blend the magnesium stearate into the resulting powder. Encapsulate the mixture into suitably sized two-piece hard gelatin capsules.

Formulation 5

| <u>Tablet</u>                | <u>Amount (mg)</u>     |                       |
|------------------------------|------------------------|-----------------------|
| Active ingredient B          | 250.0                  | 125.0                 |
| 15 Lactose                   | 161.0                  | 80.5                  |
| Corn Starch                  | 12.0                   | 6.0                   |
| Water (per thousand tablets) | 120 ml<br>(evaporates) | 60 ml<br>(evaporates) |
| Corn Starch                  | 75.0                   | 37.5                  |
| 20 Magnesium Stearate        | 2.0                    | 1.0                   |
|                              | <u>500.0</u>           | <u>250.0</u>          |

Blend the active ingredient with the lactose until uniform. Blend the smaller quantity of corn starch with the water and add the resulting corn starch paste, then mix until a uniform wet mass is formed. Add the remaining corn starch to the remaining wet mass and mix until uniform granules are obtained. Screen the

granules through a suitable milling machine, using a 3/4 inch stainless steel screen. Dry the milled granules in a suitable drying oven until the desired moisture content is obtained. Mill the dried granules through a 5 suitable milling machine using a 16 mesh stainless steel screen. Blend in the magnesium stearate and compress the resulting mixture into tablets of desired shape, thickness, hardness and disintegration.

|    | <u>Formulation 6</u>        | <u>mg/ml</u> |
|----|-----------------------------|--------------|
| 10 | <u>Injectable Solution</u>  |              |
|    | Active ingredient B         | 5.00         |
|    | Methyl p-hydroxybenzoate    | 0.80         |
|    | Propyl p-hydroxybenzoate    | 0.10         |
|    | Disodium Edetate            | 0.10         |
| 15 | Citric Acid Monohydrate     | 0.08         |
|    | Dextrose                    | 40.0         |
|    | Water for injection qs. ad. | 1.0 ml       |

20 Dissolve the p-hydroxybenzoates in a portion of water for injection at 60-70°C and cool the solution to 25-35°C. Charge and dissolve all other excipients and the active ingredient. Bring the solution to final volume, filter it through a sterilizing membrane and fill into sterile containers.

Formulation 7

| <u>Capsule</u>      | <u>Amount (mg)</u> |              |
|---------------------|--------------------|--------------|
| Active ingredient C | 250.0              | 125.0        |
| Lactose             | 173.0              | 86.5         |
| 5 Corn Starch       | 75.0               | 37.5         |
| Magnesium Stearate  | 2.0                | 1.0          |
|                     | <u>500.0</u>       | <u>250.0</u> |

Blend the active ingredient, lactose and corn starch until uniform; then blend the magnesium stearate into the  
 10 resulting powder. Encapsulate the mixture into suitably sized two-piece hard gelatin capsules.

Formulation 8

| <u>Tablet</u>                | <u>Amount (mg)</u> |              |
|------------------------------|--------------------|--------------|
| Active ingredient C          | 250.0              | 125.0        |
| 15 Lactose                   | 161.0              | 80.5         |
| Corn Starch                  | 12.0               | 6.0          |
| Water (per thousand tablets) | 120 ml             | 60 ml        |
|                              | (evaporates)       | (evaporates) |
| Corn Starch                  | 75.0               | 37.5         |
| 20 Magnesium Stearate        | 2.0                | 1.0          |
|                              | <u>500.0</u>       | <u>250.0</u> |

Blend the active ingredient with the lactose until uniform. Blend the smaller quantity of corn starch with the water and add the resulting corn starch paste, then  
 25 mix until a uniform wet mass is formed. Add the remaining corn starch to the remaining wet mass and mix until uniform granules are obtained. Screen the granules through a suitable milling machine, using a 3/4 inch stainless steel screen. Dry the milled granules in a  
 30 suitable drying oven until the desired moisture content is obtained. Mill the dried granules through a suitable milling machine using a 16 mesh stainless steel screen. Blend in the magnesium stearate and compress the resulting mixture into tablets of desired shape,  
 35 thickness, hardness and disintegration.

0088350

- 115 -


Formulation 9

| <u>Injectable Solution</u>  | <u>mg/ml</u> |
|-----------------------------|--------------|
| Active ingredient C         | 5.00         |
| Methyl p-hydroxybenzoate    | 0.80         |
| 5 Propyl p-hydroxybenzoate  | 0.10         |
| Disodium Edetate            | 0.10         |
| Citric Acid Monohydrate     | 0.08         |
| Dextrose                    | 40.0         |
| Water for injection qs. ad. | 1.0 ml       |

10 Dissolve the p-hydroxybenzoates in a portion of water for injection at 60-70°C and cool the solution to 25-35°C. Charge and dissolve all other excipients and the active ingredient. Bring the solution to final volume; filter it through a sterilizing membrane and fill into sterile 15 containers.


We claim:

1) A compound of the formula




the pharmaceutically acceptable esters thereof and the  
5 pharmaceutically acceptable salts of the foregoing,  
wherein





R<sup>1</sup> and R<sup>2</sup> independently are hydrogen or lower alkyl;

the group  is one of the structures II to VIII




10






(wherein B is a saturated or aromatic ring) or




one of  $R^3$ ,  $R^4$  and  $R^5$  is a group  $Z-(CH_2)_{0-6}-$ , wherein  $Z$  has one of the following values  $Z^1$  to  $Z^{10}$ :


$Z^1:$




$Z^2:$




$Z^3:$








$Z^4:$



$Z^5:$







wherein R<sup>8</sup> is Cl or CF<sub>3</sub>;

R<sup>6</sup> is hydrogen or halogen;

R<sup>7</sup> is hydrogen, halogen, carboxy, hydroxy or amino;

R<sup>9</sup> and R<sup>10</sup> are independently hydrogen, lower alkyl or halo-lower alkyl and R<sup>9</sup> can also be phenyl or phenyl lower alkyl;

R<sup>11</sup> is hydrogen or lower alkyl;

R<sup>12</sup> is hydrogen, lower alkyl or phenyl lower alkyl;

whereby when R<sup>3</sup> is the group Z-(CH<sub>2</sub>)<sub>0-6</sub>-, then

R<sup>3</sup> is Z<sup>1</sup>-(CH<sub>2</sub>)<sub>1-6</sub>-, Z<sup>2</sup>-(CH<sub>2</sub>)<sub>1-6</sub>-, Z<sup>3</sup>-(CH<sub>2</sub>)<sub>1-6</sub>-,

Z<sup>4</sup>-CH<sub>2</sub>-, Z<sup>5</sup>-(CH<sub>2</sub>)<sub>1-6</sub>-, Z<sup>6</sup>-(CH<sub>2</sub>)<sub>1-6</sub>-, Z<sup>7</sup>-(CH<sub>2</sub>)<sub>1-6</sub>-,

Z<sup>8</sup>-(CH<sub>2</sub>)<sub>1-6</sub>-, Z<sup>9</sup>-(CH<sub>2</sub>)<sub>1-6</sub>-, or Z<sup>10</sup>-(CH<sub>2</sub>)<sub>1-6</sub>-;

R<sup>4</sup> is lower alkyl, benzyl, benzyloxy, benzylthio, phenoxy, or phenylthio,

or

R<sup>5</sup> is hydrogen; and the group -N-C- is one of the structures II to VIII;

and when  $R^4$  is the group  $Z-(CH_2)_{0-6}-$ , then

$R^4$  is  $Z^1-(CH_2)_{0-6}-$ ,  $Z^2-(CH_2)_{0-6}-$ ,  $Z^3-(CH_2)_{0-6}-$ ,

$Z^4-(CH_2)_{0-6}-$ ,  $Z^5-(CH_2)_{0-6}-$ ,  $Z^6-(CH_2)_{0-6}-$ ,  $Z^7-(CH_2)_{0-6}-$ ,

$Z^8-(CH_2)_{0-6}-$ ,  $Z^9-(CH_2)_{0-6}-$  or  $Z^{10}-(CH_2)_{0-6}-$  and

$R^3$  is hydrogen, lower alkyl or amino lower alkyl and

$R^5$  is hydrogen; and the group  $-N-C-$  is one of the structures II to VIII;

and when  $R^5$  is the group  $Z-(CH_2)_{0-6}-$ , then  $R^5$  is  $Z^1$ ,  $Z^2$ ,  $Z^3$ ,  $Z^4$ ,  $Z^5$ ,  $Z^6$ ,  $Z^7$ ,  $Z^8$ ,  $Z^9$  or  $Z^{10}$ ,

$R^3$  is hydrogen, lower alkyl or amino lower alkyl and

$R^4$  is lower alkyl, benzyl, benzyloxy, benzylthio, phenoxy or phenyl-thio; and

the group  $-N-C-$  is one of the structures II to VII, preferably being in the form of the free di-carbonic acid or in the form of its alkyl ester, the alkyl group containing 1 to 6 carbon atoms, especially in the form of its monoester wherein the carboxy group attached to the group

$-N-C-$  is in the free form,

preferably all former compounds being the stereoisomer in which the absolute configurations at each of the three carbon atoms bonded to both a nitrogen and a carbonyl group corresponds most closely to the absolute configuration of L-aminoacids.

0088350

2) A compound according to claim 1, wherein  $R^4$  is a group  $Z-(CH_2)_{0-6}-$  as defined in claim 1, wherein Z preferably is  $Z^1, Z^2, Z^3, Z^5, Z^7, Z^8, Z^9$  or  $Z^{10}$ ;

$R^4$  preferably being  $Z^1-(CH_2)_2$  or  $3^-, Z^2-(CH_2)_2$  or  $3^-$ ,  $Z^3-(CH_2)_2$  or  $3^-$ ,  $Z^5-(CH_2)_2$  or  $3^-$ ,  $Z^7-(CH_2)_2$  or  $3^-$ ,  $Z^8-(CH_2)_2$  or  $3^-$ ,  $Z^9-(CH_2)_2$  or  $3^-$  or  $Z^{10}-(CH_2)_2$  or  $3^-$ ,


and wherein preferably the group



$-N-C-$  is the group of formula II, IV (wherein B is a saturated ring) or VIII, preferably  $R^5$  being hydrogen.

3) A compound according to claim 1 or 2, wherein  $R^1$  and  $R^2$  are hydrogen, and/or when Z is of the formula IX, X or XI  $R^6$  is hydrogen and  $R^7$  is hydrogen or hydroxy, and/or when Z is of the formula XIII or XIV  $R^9$  and  $R^{10}$  are independently hydrogen or methyl, and/or  $R^8$  in the definition of the moiety Z is chloro, and/or  $R^3$  is methyl.

4) A compound according to claim 1 or 2, wherein  $R^1$  and  $R^2$  are hydrogen, the group



$-N - \overset{A}{\underset{|}{C}} - R^5$  is the group of formula IV, wherein B is a saturated ring and  $R^5$  is hydrogen,  $R^4$  is  $Z^1-(CH_2)_3-$  or  $Z^2-(CH_2)_3-$ , wherein  $R^6$  is hydrogen,  $R^7$  is hydrogen or hydroxy, and  $R^8$  is chloro; and  $R^3$  is methyl, preferably being

$1-\{N-[1(S)-ethoxycaronyl-5-(4-chloro-3-sulfamoyl)-benzenesulfonaminopentyl]-(S)-alanyl\}-cis, syn-octahydro-1H-indole-2(S)-carboxylic acid,$

$1-\{N-[1(S)-ethoxycarbonyl-5-(4-chloro-3-sulfamoyl)-benzamidopentyl]-(S)-alanyl\}-cis, syn$ -octahydro-1H-indole-2(S)-carboxylic acid, or


$1-\{N-[1(S)-ethoxycarbonyl-5-(4-chloro-2-hydroxy-5-sulfamoyl)-benzamidopentyl]-(S)-alanyl\}-cis, syn$ -octahydro-1H-indole-2(S)-carboxylic acid,

$1-\{N-[1(S)-CARBOXY-5-[(4-CHLORO-2-HYDROXY-5-SULFAMOYL) PHENYL] CARBONYL]AMINO]PENTYL\}-(S)-ALANYL\}-CIS, SYN$ -OCTAHYDRO-1H-INDOLE-2(S)-CARBOXYLIC ACID,

$1-\{N-[1(S)-CARBOXY-5-[(4-CHLORO-3-(N-METHYL SULFAMOYL) PHENYL) CARBONYL]AMINO]PENTYL\}-(S)-ALANYL\}-CIS, SYN$ -OCTAHYDRO-1H-INDOLE-2(S)-CARBOXYLIC ACID,

$1-\{N-[1(S)-CARBOXY-5-[(4-CHLORO-3-SULFAMOYL PHENYL) CARBONYL]AMINO]PENTYL\}-(S)-ALANYL\}-CIS, SYN$ -OCTAHYDRO-1H-INDOLE-2(S)-CARBOXYLIC ACID,

in the free form or in the form of its ester, preferably in the form of its mono-or-di-ethyl ester.


5) A compound according to claim 1, wherein  $R^3$  is a group  $Z-(CH_2)_{0-6}-$  as defined in claim 1, preferably  $Z^1-(CH_2)_4-$ ,  $Z^2-(CH_2)_4-$ ,  $Z^3-(CH_2)_4-$ ,  $Z^4-CH_2-$ ,  $Z^5-(CH_2)_4-$ ,  $Z^6-(CH_2)_4-$ ,  $Z^7-(CH_2)_4-$ ,  $Z^8-(CH_2)_4-$ ,  $Z^9-(CH_2)_4-$  or  $Z^{10}-(CH_2)_4-$ , and wherein the group  is preferably the group of formula II, IV (wherein B is a saturated ring) or VIII.


6) A compound according to claim 5, wherein  $R^1$  and  $R^2$  are hydrogen, and/or Z is of the formula IX, X or XI,  $R^6$  is hydrogen and  $R^7$  is hydrogen or hydroxy, and/or when Z is of the formula XIII or XIV  $R^9$  and  $R^{10}$  are independently hydrogen or methyl, and/or  $R^8$  in the definition of the moiety Z is chloro, and/or  $R^4$  is benzyl or ethyl.

7) A compound according to claim 5, wherein  $R^1$  and  $R^2$  are hydrogen, the group  is the group of formula IV, wherein B is a saturated ring and  $R^5$  is hydrogen,  $R^3$  is  $Z^1-(CH_2)_4-$  or  $Z^2-(CH_2)_4-$ , wherein  $R^6$  and  $R^7$  are hydrogen, and  $R^8$  is chloro, and  $R^4$  is benzyl, preferably being

1-{Na-[1(S)-ethoxycarbonyl-3-phenylpropyl]-Nε-[ (4-chloro-3-sulfamoyl)benzenesulfonyl]-(S)-lysyl}-cis, syn-octahydro-1H-indole-2(S)-carboxylic acid or  
1-{Na-[1(S)-ethoxycarbonyl-3-phenylpropyl]-Nε-[ (4-chloro-3-sulfamoyl)benzoyl-(S)-lysyl}-cis, syn-octahydro-1H-indole-2(S)-carboxylic acid  
5

in the free form or in the form of its ester, preferably in the form of its mono-or-di-ethyl ester.

8) A compound according to claim 1, wherein R<sup>5</sup> is a  
10 group Z-(CH<sub>2</sub>)<sub>0-6</sub>- as defined in claim 1, preferably being z<sup>1</sup>, z<sup>2</sup>, z<sup>3</sup>, z<sup>5</sup>, z<sup>7</sup>, z<sup>8</sup>, z<sup>9</sup> or z<sup>10</sup>; wherein the group  
group   
-N-C- is preferably the group of formula II, VI  
(wherein B is an aromatic ring), or IV (wherein B is a saturated ring), preferably




9) A compound according to claim 8, wherein R<sup>1</sup> and R<sup>2</sup> are hydrogen, and/or when Z is of the formula IX, X or XI R<sup>6</sup> is hydrogen and R<sup>7</sup> is hydrogen or hydroxy, and/or when Z is of the formula XIII or XIV R<sup>9</sup> and R<sup>10</sup> are

independently hydrogen or methyl, and/or R<sup>8</sup> in the definition of the moiety Z is chloro, and/or R<sup>3</sup> is methyl and/or R<sup>4</sup> is benzyl or ethyl,

the compound preferably being


5 7-(4-chloro-3-sulfamoylbenzamido)-2-[N-[1(S)-ethoxycarbonyl-3-phenylpropyl)-(S)-alanyl]-1,2,3,4-tetrahydroisoquinoline-3(S)-carboxylic acid or the corresponding 1-S-carboxy-compound.

10) Process for the preparation of a compound of formula  
10 I as defined in any one of claims 1 to 9, characterized  
in that the compound is prepared by an appropriate process  
selected from the following processes a to i:  
a) for the preparation of a compound of formula I, wherein  
R<sup>1</sup> is hydrogen: condensation of a ketocompound (XIX) with  
15 a depeptide (XX) under reduction




wherein A, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are as define above and Pr stands for a free or a protected hydroxy group;

b) alkylation of a dipeptide (XX) by means of a compound  
20 of formula (XXI) under basic conditions




wherein X is chloro, bromo, iodo, alkanesulfonyloxy or arenesulfonyloxy, A, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> are as defined above for compounds of formula I and Pr stands for a free 5 or protected hydroxy group;

c) condensation of an aminoacid (XXII) with an aminoacid (XXIII) in the presence of a condensing agent




wherein A, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> are as defined above for 10 compounds of formula I, and Pr stands for a free or protected (e.g. by esterification) hydroxy group ;

d) condensation of an amino compound (XXIV) with a keto-compound (XXV)



under the conditions described for process a wherein A, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> are as defined above for compounds of formula I and Pr stands for a free or protected (e.g. by esterification) hydroxy group;


5 e) alkylation of an amino compound (XXIV) by means of a compound (XXVI)



wherein X is chloro, bromo, iodo, alkanesulfonyloxy or arenesulfonyloxy, A, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> are as defined


10 above for compounds of formula I and Pr stands for a free or protected (e.g. by esterification) hydroxy group, under the conditions described for process b;

f) for the preparation of a compound of formula I, wherein one of R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> is a group Z-(CH<sub>2</sub>)<sub>0-6-</sub>, 15 wherein Z is Z<sup>5</sup>, Z<sup>6</sup>, Z<sup>7</sup> Z<sup>8</sup>, Z<sup>9</sup> or Z<sup>10</sup>, preferably Z<sup>7</sup>, Z<sup>8</sup> or Z<sup>9</sup>: condensation of a peptide of the general formula (XXX) with a compound containing the desired group (XXXI)



wherein R<sup>1</sup>, R<sup>2</sup> and A are as defined for formula I, Pr is a protected hydroxy group W<sup>3</sup>, W<sup>4</sup> and W<sup>5</sup> are defined like R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> respectively with the difference that one of W<sup>3</sup>, W<sup>4</sup> and W<sup>5</sup> contains an NH<sub>2</sub>-group instead of the respective z<sup>5</sup> to z<sup>10</sup>-group; and W<sup>6</sup> is z<sup>5</sup>, z<sup>6</sup>, z<sup>7</sup>, z<sup>8</sup>, z<sup>9</sup> or z<sup>10</sup>;


g) for the preparation of a compound of formula I, wherein one of R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> is a group Z-(CH<sub>2</sub>)<sub>0-6</sub>-<sup>10</sup>, wherein Z is z<sup>1</sup>, z<sup>2</sup> or z<sup>3</sup>: condensation of a peptide of formula XXXII with an appropriately substituted compound of formula XXXIII




XXXII

XXXIII


wherein R<sup>1</sup>, R<sup>2</sup> and A are as defined for formula I, Pr is a protected hydroxy group, W<sup>7</sup>, W<sup>8</sup> and W<sup>9</sup> are defined like R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> respectively, with the difference that one of W<sup>7</sup>, W<sup>8</sup> and W<sup>9</sup> contains an NH<sub>2</sub>-group instead of the respective z<sup>1</sup>, z<sup>2</sup> or z<sup>3</sup> group, and W<sup>10</sup> is



XXXIV




XXXV




XXXVI

h) for the preparation of a compound of formula I,  
 wherein one of R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> is a group Z-(CH<sub>2</sub>)<sub>0-6</sub>-,  
 wherein Z is Z<sup>4</sup>: condensation of a peptide of formula  
 (XXXVII) with a 3 halomethylbenzothiadiazine (XXXVIII)




wherein R<sup>1</sup>, R<sup>2</sup> and A are as defined for formula I, Pr is a protected hydroxy group, W<sup>11</sup>, W<sup>12</sup> and W<sup>13</sup> are defined like R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> respectively with the difference that one of 10 W<sup>11</sup>, W<sup>12</sup> and W<sup>13</sup> contains a -SH-group instead of the respective Z<sup>4</sup>-group, and Hal is halogen, preferably chloro;

i) for the preparation of a compound of formula I,  
 wherein one of  $R^3$ ,  $R^4$  and  $R^5$  is a group  $Z-(CH_2)_{0-6}-$ ,  
 wherein  $Z$  is  $Z^5$  or  $Z^6$ : condensation of a peptide of  
 formula XXXIX with a compound of formula XXXX



wherein  $R^1$ ,  $R^2$ ,  $R^9$ ,  $R^{10}$  and A are as defined for formula I,  
 $Pr$  is a protected hydroxy group,  $W^{14}$ ,  $W^{15}$  and  $W^{16}$  are de-  
 fined like  $R^3$ ,  $R^4$  and  $R^5$  respectively with the difference  
 that one of  $W^{14}$ ,  $W^{15}$  and  $W^{16}$  contains the group



instead of the group  $Z^5$  or  $Z^6$  respectively;

followed by removal of the protecting groups, if necessary,  
 to yield the desired product, and if desired, converting  
 a so obtained compound of formula I into its ester and/or  
 setting free the compound of formula I from its ester or  
 preparing a salt thereof and, if desired, isolating the  
 preferred isomer.


0088350

-131 -

11) A pharmaceutical composition comprising a compound of the general formula I or pharmaceutically acceptable salt or ester thereof as defined in any one of claims 1 to 9 or obtained according to a process of claim 10.

## Claims for Austria


1) process for the preparation of compound of the formula




the pharmaceutically acceptable esters thereof and the  
5 pharmaceutically acceptable salts of the foregoing,  
wherein


$R^1$  and  $R^2$  independently are hydrogen or lower alkyl;

the group  $\text{—N}(\text{A})\text{—C}(\text{R}^5)$  is one of the structures II to VIII







IV



V




VI



VII


5 (wherein B is a saturated or aromatic ring) or




VIII

one of  $R^3$ ,  $R^4$  and  $R^5$  is a group  $Z-(CH_2)_{0-6}-$ , wherein  $Z$  has one of the following values  $Z^1$  to  $Z^{10}$ :


$Z^1:$




$Z^2:$




5       $Z^3:$







$Z^4:$




$Z^5:$





z<sup>10</sup>:



XVIII

wherein R<sup>8</sup> is Cl or CF<sub>3</sub>;

R<sup>6</sup> is hydrogen or halogen;

R<sup>7</sup> is hydrogen, halogen, carboxy, hydroxy or amino;

5 R<sup>9</sup> and R<sup>10</sup> are independently hydrogen, lower alkyl or halo-lower alkyl and R<sup>9</sup> can also be phenyl or phenyl lower alkyl;

R<sup>11</sup> is hydrogen or lower alkyl;

R<sup>12</sup> is hydrogen, lower alkyl or phenyl lower alkyl;

10 whereby when R<sup>3</sup> is the group z-(CE<sub>2</sub>)<sub>0-6</sub>-, then

R<sup>3</sup> is z<sup>1</sup>-(CE<sub>2</sub>)<sub>1-6</sub>-, z<sup>2</sup>-(CE<sub>2</sub>)<sub>1-6</sub>-, z<sup>3</sup>-(CE<sub>2</sub>)<sub>1-6</sub>-,


z<sup>4</sup>-(CE<sub>2</sub>)<sub>1-6</sub>-, z<sup>5</sup>-(CE<sub>2</sub>)<sub>1-6</sub>-, z<sup>6</sup>-(CE<sub>2</sub>)<sub>1-6</sub>-, z<sup>7</sup>-(CE<sub>2</sub>)<sub>1-6</sub>-,

z<sup>8</sup>-(CE<sub>2</sub>)<sub>1-6</sub>-, z<sup>9</sup>-(CE<sub>2</sub>)<sub>1-6</sub>-, or z<sup>10</sup>-(CE<sub>2</sub>)<sub>1-6</sub>-,

R<sup>4</sup> is lower alkyl, benzyl, benzyloxy, benzylthio, phenoxy,

15 or phenylthio,

R<sup>5</sup> is hydrogen; and the group -X-C- is one of the structures II to VIII;



0088350

and when  $R^4$  is the group  $Z-(CE_2)_{0-6}^-$ , then

$R^4$  is  $Z^1-(CE_2)_{0-6}^-$ ,  $Z^2-(CE_2)_{0-6}^-$ ,  $Z^3-(CE_2)_{0-6}^-$ ,

$Z^4-(CE_2)_{0-6}^-$ ,  $Z^5-(CE_2)_{0-6}^-$ ,  $Z^6-(CE_2)_{0-6}^-$ ,  $Z^7-(CE_2)_{0-6}^-$ ,

$Z^8-(CE_2)_{0-6}^-$ ,  $Z^9-(CE_2)_{0-6}^-$  or  $Z^{10}-(CE_2)_{0-6}^-$  and

5  $R^3$  is hydrogen, lower alkyl or amino lower alkyl and

$R^5$  is hydrogen; and the group  $-N-C-$  is one of the structures II to VIII;

and when  $R^5$  is the group  $Z-(CE_2)_{0-6}^-$ , then  $R^5$  is  $Z^1$ ,  $Z^2$ ,  $Z^3$ ,  $Z^4$ ,  $Z^5$ ,  $Z^6$ ,  $Z^7$ ,  $Z^8$ ,  $Z^9$  or  $Z^{10}$ ,

10  $R^3$  is hydrogen, lower alkyl or amino lower alkyl and

$R^4$  is lower alkyl, benzyl, benzyloxy, benzylthio, phenoxy or phenylthio; and

the group  $-N-C-$  is one of the structures II to VII,

preferably being in the form of the free di-carbonic

15 acid or in the form of its alkyl ester, the alkyl group containing 1 to 6 carbon atoms, especially in the form of its monoester wherein the carboxy group attached to the group


$-N-C-$  is in the free form,

20 preferably all former compounds being the stereoisomer in which the absolute configurations at each of the three carbon atoms bonded to both a nitrogen and a carbonyl group corresponds most closely to the absolute configuration of L-aminoacids, characterized in that the com-

pound is prepared by an appropriate process selected from the following processes a to i:


a) for the preparation of a compound of formula I,

5 wherein  $R^1$  is hydrogen: condensation of a ketocompound (XIX) with a depeptide (XX) under reduction



wherein A,  $R^2$ ,  $R^3$ ,  $R^4$  and  $R^5$  are as defined above and Pr stands for a free or a protected hydroxy group;


10 b) alkylation of a dipeptide (XX) by means of a compound of formula (XXI) under basic conditions



wherein X is chloro, bromo, iodo, alkanesulfonyloxy or arenesulfonyloxy, A,  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$  are as defined

15 above for compounds of formula I and Pr stands for a free or protected hydroxy group;

c) condensation of an aminoacid (XXII) with an aminoacid (XXIII) in the presence of a condensing agent




XXII

XXIII

wherein A, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> are as defined above for compounds of formula I, and Pr stands for a free or protected (e.g. by esterification) hydroxy group;

5 d) condensation of an amino compound (XXIV) with a keto-compound (XXV)




XXIV

XXV

under the conditions described for process a wherein A, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> are as defined above for compounds of formula I and Pr stands for a free or protected (e.g. by esterification) hydroxy group;

e) alkylation of an amino compound (XXIV) by means of a compound (XXVI)




XXIV

XXVI


wherein X is chloro, bromo, iodo, alkanesulfonyloxy or arenesulfonyloxy, A, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> are as defined above for compounds of formula I and Pr stands for a free or protected (e.g. by esterification) hydroxy group, under 5 the conditions described for process b;

f) for the preparation of a compound of formula I, wherein one of R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> is a group Z-(CH<sub>2</sub>)<sub>0-6</sub>-<sup>-</sup>, wherein Z is Z<sup>5</sup>, Z<sup>6</sup>, Z<sup>7</sup> Z<sup>8</sup>, Z<sup>9</sup> or Z<sup>10</sup>, preferably Z<sup>7</sup>, Z<sup>8</sup> or Z<sup>9</sup>: condensation of a peptide of the general formula 10 (XXX) with a compound containing the desired group (XXXI)



wherein R<sup>1</sup>, R<sup>2</sup> and A are as defined for formula I, Pr is a protected hydroxy group W<sup>3</sup>, W<sup>4</sup> and W<sup>5</sup> are defined like R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> respectively with the difference that one 15 of W<sup>3</sup>, W<sup>4</sup> and W<sup>5</sup> contains an NE<sub>2</sub>-group instead of the respective Z<sup>5</sup> to Z<sup>10</sup>-group; and W<sup>6</sup> is Z<sup>5</sup>, Z<sup>6</sup>, Z<sup>7</sup>, Z<sup>8</sup>, Z<sup>9</sup> or Z<sup>10</sup>;


g) for the preparation of a compound of formula I, 20 wherein one of R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> is a group Z-(CH<sub>2</sub>)<sub>0-6</sub>-<sup>-</sup>, wherein Z is Z<sup>1</sup>, Z<sup>2</sup> or Z<sup>3</sup>: condensation of a peptide of formula XXXII with an appropriately substituted compound of formula XXXIII




XXXII

XXXIII

wherein R<sup>1</sup>, R<sup>2</sup> and A are as defined for formula I, Pr is a protected hydroxy group, W<sup>7</sup>, W<sup>8</sup> and W<sup>9</sup> are defined like R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> respectively, with the difference that one of W<sup>7</sup>, W<sup>8</sup> and W<sup>9</sup> contains an NE<sub>2</sub>-group instead of the respective z<sup>1</sup>, z<sup>2</sup> or z<sup>3</sup> group, and W<sup>10</sup> is




XXXIV





10

xxxv



xxxvi


h) for the preparation of a compound of formula I,  
 wherein one of R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> is a group Z-(CH<sub>2</sub>)<sub>0-6</sub>-,  
 10 wherein Z is Z<sup>4</sup>: condensation of a peptide of formula  
 (XXXVII) with a 3 halomethylbenzothiadiazine (XXXVIII)



XXXVII

wherein  $\text{R}^1$ ,  $\text{R}^2$  and  $\text{A}$  are as defined for formula I,  $\text{Pr}$  is a protected hydroxy group,  $\text{R}^{11}$ ,  $\text{R}^{12}$  and  $\text{R}^{13}$  are defined like  
 5  $\text{R}^3$ ,  $\text{R}^4$  and  $\text{R}^5$  respectively with the difference that one of  
 $\text{R}^{11}$ ,  $\text{R}^{12}$  and  $\text{R}^{13}$  contains a  $-\text{SE}-$ group instead of the re-  
 spective  $\text{Z}^4$ -group, and  $\text{Hal}$  is halogen, preferably chloro;

i) for the preparation of a compound of formula I,  
 wherein one of  $\text{R}^3$ ,  $\text{R}^4$  and  $\text{R}^5$  is a group  $\text{Z}-(\text{CE}_2)_{0-6}-$ ,  
 10 wherein  $\text{Z}$  is  $\text{Z}^5$  or  $\text{Z}^6$ : condensation of a peptide of  
 formula XXXIX with a compound of formula XXXX




XXXIX


XXXX

0088350

wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^{10}$  and  $\lambda$  are as defined for formula I,  $R^4$  is a protected hydroxy group,  $R^{14}$ ,  $R^{15}$  and  $R^{16}$  are defined like  $R^3$ ,  $R^4$  and  $R^5$  respectively with the difference that one of  $R^{14}$ ,  $R^{15}$  and  $R^{16}$  contains the group



or



respectively

XXXXI

XXXXI a

instead of the group  $Z^5$  or  $Z^6$  respectively;

followed by removal of the protecting groups, if necessary, to yield the desired product, and if desired, converting a so obtained compound of formula I into its ester and/or setting free the compound of formula I from its ester or preparing a salt thereof and, if desired, isolating the preferred isomer.

2) Process according to claim 1, characterized in that a compound is prepared wherein  $R^4$  is a group  $Z-(CH_2)_{0-6}-$  as defined in claim 1, wherein  $Z$  preferably is  $Z^1$ ,  $Z^2$ ,  $Z^3$ ,  $Z^5$ ,  $Z^7$ ,  $Z^8$ ,  $Z^9$  or  $Z^{10}$ ;

$R^4$  preferably being  $Z^1-(CH_2)_2$  or  $3^-$ ,  $Z^2-(CH_2)_2$  or  $3^-$ ,  $Z^3-(CH_2)_2$  or  $3^-$ ,  $Z^5-(CH_2)_2$  or  $3^-$ ,  $Z^7-(CH_2)_2$  or  $3^-$ ,  $Z^8-(CH_2)_2$  or  $3^-$ ,  $Z^9-(CH_2)_2$  or  $3^-$  or  $Z^{10}-(CH_2)_2$  or  $3^-$ .

and wherein preferably the group



-N - C- is the group of formula II, IV (wherein B is a saturated ring) or VIII, preferably R<sup>5</sup> being hydrogen.

3) Process according to claim 1 or 2, characterized in

5 that a compound is prepared, wherein R<sup>1</sup> and R<sup>2</sup> are hydrogen, and/or when Z is of the formula IX, X or XI R<sup>6</sup> is hydrogen and R<sup>7</sup> is hydrogen or hydroxy, and/or when Z is of the formula XIII or XIV R<sup>9</sup> and R<sup>10</sup> are independently hydrogen or methyl, and/or R<sup>8</sup> in the definition of the  
10 moiety Z is chloro, and/or R<sup>3</sup> is methyl.

4) Process according to claim 1 or 2, characterized in

that a compound is prepared, wherein R<sup>1</sup> and R<sup>2</sup> are hydrogen, the group



15 -N - C- is the group of formula IV, wherein B is a saturated ring and R<sup>5</sup> is hydrogen, R<sup>4</sup> is z<sup>1</sup>-(CH<sub>2</sub>)<sub>3</sub>- or z<sup>2</sup>-(CH<sub>2</sub>)<sub>3</sub>-, wherein R<sup>6</sup> is hydrogen, R<sup>7</sup> is hydrogen or hydroxy, and R<sup>8</sup> is chloro; and R<sup>3</sup> is methyl, preferably being

1- $\{N-[1(S)-ethoxycarbonyl-5-(4-chloro-3-sulfamoyl)-benzenesulfonamidopentyl)-(S)-alanyl\}$ -cis, syn-octahydro-1E-indole-2(S)-carboxylic acid,

5 1- $\{N-[1(S)-ethoxycarbonyl-5-(4-chloro-3-sulfamoyl)-benzamidopentyl)-(S)-alanyl\}$ -cis, syn-octahydro-1E-indole-2(S)-carboxylic acid, or

1- $\{N-[1(S)-ethoxycarbonyl-5-(4-chloro-2-hydroxy-5-sulfamoyl)-benzamidopentyl)-(S)-alanyl\}$ -cis, syn-octahydro-1E-indole-2(S)-carboxylic acid,

10 1- $\{N-[1(S)-CARBOXY-5-[(4-CHLORO-2-HYDROXY-5-SULFAMOYL PHENYL) CARBONYL]AMINO]PENTYL)-(S)-ALANYL\}$ -CIS, SYN-OCTAHYDRO-1H-INDOLE-2(S)-CARBOXYLIC ACID,

1- $\{N-[1(S)-CARBOXY-5-[(4-CHLORO-3-(N-METHYL SULFAMOYL) PHENYL) CARBONYL]AMINO]PENTYL)-(S)-ALANYL\}$ -CIS, SYN-OCTAHYDRO-1E-INDOLE-2(S)-CARBOXYLIC ACID,

15 1- $\{N-[1(S)-CARBOXY-5-[(4-CHLORO-3-SULFAMOYL PHENYL) CARBONYL]AMINO]PENTYL)-(S)-ALANYL\}$ -CIS, SYN-OCTAHYDRO-1H-INDOLE-2(S)-CARBOXYLIC ACID,

in the free form or in the form of its ester, preferably  
20 in the form of its mono-or-di-ethyl ester.

5) Process according to claim 1, characterized in that a compound is prepared, wherein R<sup>3</sup> is a group z-(CH<sub>2</sub>)<sub>0-6</sub> as defined in claim 1, preferably z<sup>1</sup>-(CH<sub>2</sub>)<sub>4</sub>-, z<sup>2</sup>-(CH<sub>2</sub>)<sub>4</sub>-, z<sup>3</sup>-(CH<sub>2</sub>)<sub>4</sub>-, z<sup>4</sup>-CH<sub>2</sub>-, z<sup>5</sup>-(CH<sub>2</sub>)<sub>4</sub>-, z<sup>6</sup>-(CH<sub>2</sub>)<sub>4</sub>-, z<sup>7</sup>-(CH<sub>2</sub>)<sub>4</sub>-, z<sup>8</sup>-(CH<sub>2</sub>)<sub>4</sub>-, z<sup>9</sup>-(CH<sub>2</sub>)<sub>4</sub>- or z<sup>10</sup>-(CH<sub>2</sub>)<sub>4</sub>-, and wherein the



group  $-N - C -$  is preferably the group of formula II, IV  
(wherein B is a saturated ring) or VIII.

6) Process according to claim 5, characterized in that a compound is prepared, wherein  $R^1$  and  $R^2$  are hydrogen,  
5 and/or Z is of the formula IX, X or XI,  $R^6$  is hydrogen and  $R^7$  is hydrogen or hydroxy, and/or when Z is of the formula XIII or XIV  $R^9$  and  $R^{10}$  are independently hydrogen or methyl, and/or  $R^8$  in the definition of the moiety Z is chloro, and/or  $R^4$  is benzyl or ethyl.

10 7) Process according to claim 5, characterized in that a compound is prepared, wherein  $R^1$  and  $R^2$  are hydrogen, the


group  $-N - C -$  is the group of formula IV, wherein B is a  
saturated ring and  $R^5$  is hydrogen,  $R^3$  is  $Z^1-(CH_2)_4-$  or  
 $Z^2-(CH_2)_4-$ , wherein  $R^6$  and  $R^7$  are hydrogen, and  $R^8$  is  
15 chloro, and  $R^4$  is benzyl, preferably being

1- $\{Na-[1(S)-ethoxycarbonyl-3-phenylpropyl]-Ne-[ (4-chloro-3-sulfamoyl)benzenesulfonyl]-(S)-lysyl\}-cis, syn-octahydro-1E-indole-2(S)-carboxylic acid or$


1- $\{Na-[1(S)-ethoxycarbonyl-3-phenylpropyl]-Ne-[(4-chloro-3-sulfamoyl)benzoyl-(S)-lysyl\}-cis, syn-octahydro-1E-indole-2(S)-carboxylic acid$

in the free form or in the form of its ester, preferably in the form of its mono-or-di-ethyl ester.

8) Process according to claim 1, characterized in that a compound is prepared, wherein  $R^5$  is a group  $Z-(CH_2)_{0-6}-$  as defined in claim 1, preferably being  $Z^1, Z^2, Z^3, Z^5, Z^7,$  5  $Z^8, Z^9$  or  $Z^{10}$ ; wherein the group



$-N-A-C-$  is preferably the group of formula II, VI (wherein B is an aromatic ring), or IV (wherein B is a saturated ring), preferably



9) Process according to claim 8, characterized in that a compound is prepared, wherein  $R^1$  and  $R^2$  are hydrogen, and/or when Z is of the formula IX, X or XI  $R^6$  is hydrogen and  $R^7$  is hydrogen or hydroxy, and/or when Z is of the 15 formula XIII or XIV  $R^9$  and  $R^{10}$  are independently hydrogen or methyl, and/or  $R^8$  in the definition of the moiety Z is chloro, and/or  $R^3$  is methyl and/or  $R^4$  is benzyl or ethyl,

the compound preferably being

7-(4-chloro-3-sulfamoylbenzamido)-2-[N-[1(S)-ethoxycarbonyl-3-phenylpropyl]-(S)-alanyl]-

1,2,3,4-tetrahydroisoquinoline-3(S)-carboxylic

5 acid or the corresponding 1-S-carboxy-compound.

10) Process for the preparation of a pharmaceutical composition comprising a compound of the general formula I or pharmaceutically acceptable salt or ester thereof as defined in any one of claims 1 to 9, characterized in

10 that active ingredient is brought into a form suitable for therapeutic application.



European Patent  
Office

EUROPEAN SEARCH REPORT

0088350.

EP 83 10 2014

| DOCUMENTS CONSIDERED TO BE RELEVANT  |   |                      |  |
|--|---|----------------------|--|
| Category   | Citation of document with indication, where appropriate, of relevant passages     | Relevant to claim    | CLASSIFICATION OF THE APPLICATION (Int. Cl. *) |
| D,A  | EP-A-0 012 401 (MERCK)<br>* Title page; pages 32-33, 46 *                         | 1,11                 | C 07 C 103/52<br>A 61 K 37/02                  |
| D,P  | EP-A-0 050 800 (SCHERING)<br>* Title page; pages 72-97,<br>101-102 *              | 1,11                 |  |
| P  | EP-A-0 065 301 (MERCK)<br>* Title page; pages 1-4, 12-13,<br>21-23 *<br><br>----- | 1,11                 |  |
| TECHNICAL FIELDS SEARCHED (Int. Cl. *)   |   |                      |  |
| C 07 C 103/00<br>A 61 K 37/00  |   |                      |  |
| The present search report has been drawn up for all claims                       |   |                      |  |
| Place of search<br>THE HAGUE   | Date of completion of the search<br>10-06-1983                                    | Examiner<br>RAJIC M. |  |
| CATEGORY OF CITED DOCUMENTS  |   |                      |  |
| X : particularly relevant if taken alone   | T : theory or principle underlying the invention                                  |                      |  |
| Y : particularly relevant if combined with another document of the same category | E : earlier patent document, but published on, or after the filing date           |                      |  |
| A : technological background   | D : document cited in the application   |                      |  |
| O : non-written disclosure   | L : document cited for other reasons  |                      |  |
| P : intermediate document  | & : member of the same patent family, corresponding document                      |                      |  |

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**